{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":245,"total_is_capped":false,"direct_labels_cover":1,"predictions_cover":245,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"83756d19b7bf","filters":{"venue":"ESMO Open"}},"results":[{"id":"W3107453141","doi":"10.1136/esmoopen-2020-001079","title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial","year":2020,"lang":"en","type":"article","venue":"ESMO Open","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":522,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Bristol-Myers Squibb Canada; National Institutes of Health; Memorial Sloan-Kettering Cancer Center","keywords":"Sunitinib; Medicine; Ipilimumab; Nivolumab; Renal cell carcinoma; Internal medicine; Gastroenterology; Oncology; Cancer; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.086461553476601,"gpt":0.333877590462352,"spread":0.247416036985751,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001684032,0.0003784766,0.001142072,0.00006145013,0.0001425077,0.00002177509,0.0004861975,0.0001194203,0.0003127932],"category_scores_gemma":[0.0001393429,0.0002598503,0.0005741235,0.0002818698,0.0001274424,0.0001114393,0.0002182658,0.0001173067,0.00001330398],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003933354,"about_ca_system_score_gemma":0.0005699875,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007365238,"about_ca_topic_score_gemma":0.0002492895,"domain_scores_codex":[0.9977703,0.00009710244,0.0007821237,0.0005390096,0.0004200525,0.0003914079],"domain_scores_gemma":[0.9979939,0.0002356165,0.0004882688,0.0008109944,0.0002150435,0.0002561071],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9711877,0.003442656,0.000164795,0.0003599974,0.0006392266,0.0001058524,0.003618451,0.0001509626,0.009708098,0.0001821506,0.00116017,0.009279929],"study_design_scores_gemma":[0.6368122,0.03132326,0.0007548517,0.00006657904,0.001038785,0.00000555148,0.0006242759,0.0003831888,0.3234068,0.00002492082,0.005358638,0.0002009297],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9854496,0.0002383781,0.0000418072,0.0009828021,0.0005797258,0.007018694,0.0002781296,0.00002754325,0.005383386],"genre_scores_gemma":[0.995093,0.00005062638,0.0009154804,0.0000585675,0.0002711157,0.0005003103,0.0002951396,0.00006444618,0.002751349],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3343755,"threshold_uncertainty_score":0.9999854,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3157783125","doi":"10.1016/j.esmoop.2021.100092","title":"Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines☆","year":2021,"lang":"en","type":"article","venue":"ESMO Open","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":505,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"William Osler Health System; McMaster University; University of Toronto","funders":"European Society for Medical Oncology; Kyowa Hakko Kirin; Celgene; Novartis; Helsinn; Amgen","keywords":"Cachexia; Guideline; Expert opinion; Medicine; Multidisciplinary approach; Clinical Practice; Cancer cachexia; Intensive care medicine; Cancer; Physical therapy; Internal medicine; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.2250451284064284,"gpt":0.5728219565235178,"spread":0.3477768281170893,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008754051,0.00009742525,0.0003419888,0.00004449661,0.0000611426,0.00004156501,0.0001480434,0.0001130777,0.001410299],"category_scores_gemma":[0.005712629,0.00009053732,0.00005147827,0.0002636509,0.00002775577,0.0002320182,0.0001763711,0.0004308903,0.0001573704],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001267922,"about_ca_system_score_gemma":0.0006816487,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005844255,"about_ca_topic_score_gemma":0.002555076,"domain_scores_codex":[0.9982013,0.0001701695,0.0008188688,0.0003292007,0.0002459855,0.000234451],"domain_scores_gemma":[0.9975528,0.0001761759,0.0001457572,0.0003128949,0.001616614,0.0001958161],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004907907,0.001280256,0.6011572,0.0001383107,0.00004828723,0.0003547971,0.0002544592,0.00000258317,0.000004532584,0.001203539,0.3431974,0.05186781],"study_design_scores_gemma":[0.005454482,0.00008096294,0.2837155,0.0005551568,0.00003931697,0.00002003742,0.0003682642,0.0001097402,0.00007008665,0.00009179015,0.7093942,0.0001004891],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.2846168,0.0009911871,0.00008974537,0.5389344,0.003225531,0.002158573,0.00004290885,0.00008998361,0.1698508],"genre_scores_gemma":[0.2281924,0.006859795,0.1127276,0.6346692,0.002001564,0.0003923319,0.000415957,0.00009229282,0.01464882],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.3661968,"threshold_uncertainty_score":0.9995025,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4324143593","doi":"10.1016/j.esmoop.2023.101155","title":"Anxiety and depression in adult cancer patients: ESMO Clinical Practice Guideline","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer survivorship and care","field":"Medicine","cited_by":259,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"European Society for Medical Oncology","keywords":"Anxiety; Depression (economics); Mindfulness; Guideline; Medicine; Clinical psychology; Cancer; Psychiatry; Population; Clinical Practice; Psychology; Internal medicine; Physical therapy","retraction":null,"screen_n_in":null,"score":{"opus":0.03869775150564856,"gpt":0.4239034952803956,"spread":0.385205743774747,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007653225,0.000105834,0.00026678,0.0000542304,0.00004701897,0.00003831965,0.0001502746,0.0001169261,0.0002331237],"category_scores_gemma":[0.001334083,0.00008655729,0.00004033665,0.0003376723,0.00003377136,0.0002611096,0.0003518333,0.0002649578,0.00005111197],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005219715,"about_ca_system_score_gemma":0.0001243437,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.0371364,"about_ca_topic_score_gemma":0.02204698,"domain_scores_codex":[0.9986621,0.0001088846,0.0004429482,0.0003545303,0.0002360561,0.0001955312],"domain_scores_gemma":[0.9990219,0.0001543619,0.0001009895,0.0002668666,0.0003225449,0.0001333345],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0004673901,0.0001208744,0.8067853,0.00002322891,0.00002180319,0.00002727072,0.0005182069,0.000002697709,0.000002426504,0.00001781732,0.1099056,0.08210742],"study_design_scores_gemma":[0.002647452,0.00008894926,0.6467898,0.0002051076,0.00004902477,0.000005332364,0.0007963994,0.0002294528,0.00005282648,0.00002363467,0.3490034,0.000108613],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9678928,0.0002104463,0.00001327384,0.008927341,0.001250045,0.0008460559,0.00003118699,0.00006217062,0.02076667],"genre_scores_gemma":[0.981301,0.003183794,0.0006064589,0.01261553,0.0003928021,0.0001462573,0.0001756995,0.00003137651,0.001547153],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2390978,"threshold_uncertainty_score":0.9957981,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3170831652","doi":"10.1016/j.esmoop.2021.100170","title":"Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts","year":2021,"lang":"en","type":"review","venue":"ESMO Open","topic":"Vascular Tumors and Angiosarcomas","field":"Medicine","cited_by":183,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Merck Sharp and Dohme; Johnson and Johnson; PharmaMar; European Society for Medical Oncology; Astellas Pharma; Eisai; Daiichi-Sankyo; Cancer Research UK; MedImmune; Sanofi; Canadian Aeronautics and Space Institute; Merck; Sarcoma UK; Desmoid Tumor Research Foundation; Roche; Novartis; GlaxoSmithKline; Boehringer Ingelheim; Amgen; Pfizer; Aimmune Therapeutics; AstraZeneca; Bristol-Myers Squibb; Eli Lilly and Company; Daiichi Sankyo Europe; National Cancer Institute; Bayer","keywords":"Epithelioid hemangioendothelioma; Medicine; Cancer; Pathology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1298996345763592,"gpt":0.4058236368459077,"spread":0.2759240022695485,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005938105,0.000481967,0.002741193,0.00006879997,0.000277051,0.00009390793,0.001325796,0.0002296934,0.002190195],"category_scores_gemma":[0.000184874,0.0002826318,0.001042642,0.0003669076,0.0002024666,0.00007126388,0.0003484581,0.0007214578,0.0000274747],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007608139,"about_ca_system_score_gemma":0.0008342993,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.04661414,"about_ca_topic_score_gemma":0.002990955,"domain_scores_codex":[0.996667,0.001534597,0.000714485,0.0004160184,0.0003507996,0.0003170939],"domain_scores_gemma":[0.9963461,0.0006523196,0.0003987771,0.002261312,0.0001504138,0.0001910699],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00005026886,0.0008257792,0.0003425112,0.0046376,0.002598169,0.0007989601,0.002663642,3.291353e-7,0.00006978804,0.0002476941,0.02218921,0.9655761],"study_design_scores_gemma":[0.0007648753,0.0001049184,0.0001556848,0.02651661,0.001675366,0.0003617551,0.001383527,5.157599e-7,0.0001956051,0.00003786661,0.9684864,0.0003169128],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0009572125,0.9926863,0.000001084309,0.0006208175,0.0001859582,0.001919379,0.000804956,0.00002884279,0.002795408],"genre_scores_gemma":[0.0007227651,0.9950441,0.0002406868,0.0009891125,0.0003386433,0.0003561411,0.001199475,0.0001134198,0.0009957054],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9652591,"threshold_uncertainty_score":0.9999626,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4378904074","doi":"10.1016/j.esmoop.2023.101567","title":"The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022","year":2023,"lang":"en","type":"review","venue":"ESMO Open","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":161,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"Amgen Astellas Biopharma; Chugai Pharmaceutical; Flatiron Health; EMD Serono; AstraZeneca; Alnylam Pharmaceuticals; Genentech; Pancreatic Cancer Action Network; Ipsen; Sumitomo Dainippon Pharma Oncology; Nordic Pharma Group; Falk Foundation; Shionogi; Astellas Pharma; Samsung; Eisai; Sirtex Medical; Cancer Research UK; Plexxikon; Seagen; GlaxoSmithKline; Advanced Accelerator Applications; BeiGene; Momenta Pharmaceuticals; Daiichi Sankyo Europe; Agios Pharmaceuticals; Merck KGaA; Gilead Sciences; Taiho Pharmaceutical; Regeneron Pharmaceuticals; Mirati Therapeutics; Boston Scientific Corporation; Karyopharm Therapeutics; Array BioPharma; Exelixis; Celgene; National Cancer Institute; Incyte; Servier; Halozyme; Kyowa Hakko Kirin; Sanofi; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb; Pfizer; Amgen; Les Laboratories Pierre Fabre","keywords":"Hepatocellular carcinoma; Medicine; Cirrhosis; Expert opinion; Gastrointestinal cancer; Liver cancer; General surgery; Cancer; Internal medicine; Intensive care medicine; Gastroenterology; Oncology; Colorectal cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.223973563722923,"gpt":0.391251917489142,"spread":0.167278353766219,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006162244,0.00056146,0.001273921,0.0001243436,0.0005048502,0.0001670237,0.000856825,0.00007877885,0.0004077388],"category_scores_gemma":[0.00003034328,0.000318168,0.0003754865,0.0004732942,0.0001800174,0.00006683268,0.0008750492,0.0005663768,0.00006782856],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002013464,"about_ca_system_score_gemma":0.0002982178,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004228001,"about_ca_topic_score_gemma":0.0005516856,"domain_scores_codex":[0.9971648,0.0004791894,0.0008050581,0.0007078981,0.0004257666,0.0004173314],"domain_scores_gemma":[0.9974235,0.0008382879,0.0005062738,0.000955752,0.00009434591,0.0001818992],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001169236,0.0001877423,0.03954416,0.002530412,0.001191388,0.0001357253,0.0001230164,7.966828e-8,3.99162e-7,0.0004652594,0.02706623,0.9286386],"study_design_scores_gemma":[0.000961169,0.0001756253,0.002844538,0.0319675,0.001166804,0.00002122173,0.000154372,0.0001560192,0.00001763953,0.00004012537,0.9622172,0.0002778091],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0005145611,0.9890854,0.000009323575,0.002212859,0.001367623,0.005629636,0.0004408487,0.00004076311,0.0006989563],"genre_scores_gemma":[0.0006891951,0.9915276,0.0003340493,0.00007708243,0.0002853888,0.002699859,0.002203303,0.00009695331,0.002086642],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9351509,"threshold_uncertainty_score":0.999927,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4390776701","doi":"10.1016/j.esmoop.2023.102195","title":"2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Nausea and vomiting management","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Ottawa Hospital; University of Ottawa","funders":"European Society for Medical Oncology; Novo Nordisk Fonden; Helsinn; American Society of Clinical Oncology; World Health Organization; AstraZeneca; Amgen; Pfizer; Daiichi Sankyo Europe; Bristol-Myers Squibb","keywords":"Nausea; Guideline; Vomiting; Medicine; Radiation therapy; Chemotherapy-induced nausea and vomiting; Chemotherapy; Oncology; Internal medicine; Antiemetic","retraction":null,"screen_n_in":null,"score":{"opus":0.03764434434872091,"gpt":0.3675748876269092,"spread":0.3299305432781883,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00098605,0.000114319,0.000232167,0.00006044516,0.00009301578,0.0001370815,0.00009451911,0.00004753545,0.00007995537],"category_scores_gemma":[0.00004733178,0.00007811035,0.0000370988,0.00009834661,0.00004940241,0.0001166589,0.000114196,0.00008421571,0.000001131649],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001557222,"about_ca_system_score_gemma":0.00003125632,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000211368,"about_ca_topic_score_gemma":0.00004730584,"domain_scores_codex":[0.9992076,0.0000276952,0.0002659709,0.0002601491,0.00009925072,0.0001393761],"domain_scores_gemma":[0.9995238,0.0001420918,0.00006635464,0.0001813009,0.00003833896,0.00004815494],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001384481,0.0002032244,0.009573797,0.002024315,0.002253193,0.00003315135,0.001888989,0.000004603431,0.02209194,0.01116678,0.06557213,0.8838034],"study_design_scores_gemma":[0.01973201,0.002303763,0.1113426,0.002398674,0.001343762,0.0001549337,0.001435635,0.03676724,0.02480652,0.006667167,0.7923251,0.0007225721],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9616583,0.004579009,0.004243739,0.02457222,0.0001998644,0.002994566,0.00001465557,0.00005054071,0.001687106],"genre_scores_gemma":[0.9829789,0.002519477,0.007814996,0.001286973,0.0002836633,0.00009077688,0.00002554775,0.00004710081,0.004952579],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8830808,"threshold_uncertainty_score":0.3185248,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3037012925","doi":"10.1136/esmoopen-2020-000820","title":"ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer","year":2020,"lang":"en","type":"article","venue":"ESMO Open","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"Merck Sharp and Dohme; Daiichi-Sankyo; Cancer Research UK; Clovis Oncology; Merck KGaA; Boehringer Ingelheim; Celgene; GlaxoSmithKline; Novartis; Pfizer; Takeda Pharmaceutical Company; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pandemic; Flexibility (engineering); Health care; Coronavirus disease 2019 (COVID-19); Economic shortage; Medicine; Cancer; Scale (ratio); Business; Lung cancer; Intensive care medicine; Risk analysis (engineering); Medical emergency; Political science; Economics; Disease; Law; Oncology; Pathology; Geography","retraction":null,"screen_n_in":null,"score":{"opus":0.1989447492378444,"gpt":0.4751496173103141,"spread":0.2762048680724697,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002343151,0.0001135072,0.000211484,0.00005528066,0.0001457472,0.00005941278,0.0001568854,0.00003767086,0.0007733211],"category_scores_gemma":[0.00008951857,0.00007563353,0.00002630371,0.0002547543,0.00002141595,0.00008620149,0.0001137006,0.0001293718,0.00001321329],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004342712,"about_ca_system_score_gemma":0.0004046099,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.03181344,"about_ca_topic_score_gemma":0.01610371,"domain_scores_codex":[0.9991525,0.00009759807,0.0001866742,0.0002459754,0.0001242157,0.0001930214],"domain_scores_gemma":[0.999284,0.0001406685,0.00004504808,0.0002132836,0.00001658627,0.0003003893],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001343963,0.0005564572,0.3024375,0.0007493476,0.0004983886,0.0007424451,0.03986263,0.00009583154,0.00001045905,0.005376939,0.4541175,0.1942085],"study_design_scores_gemma":[0.003202252,0.000276545,0.2215523,0.00006674346,0.0001079224,0.000009204502,0.001077708,0.0004451557,0.000008736778,0.00006017003,0.773106,0.00008725392],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.02936644,0.0004273639,0.0001384462,0.9580196,0.00008195759,0.002833063,0.00004043494,0.00003496884,0.0090577],"genre_scores_gemma":[0.8215616,0.002186982,0.0005108786,0.1738925,0.0001140855,0.0004095697,0.00007936475,0.0000145554,0.001230495],"genre_candidate":"commentary","genre_consensus":null,"teacher_disagreement_score":0.7921951,"threshold_uncertainty_score":0.9746338,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2485154160","doi":"10.1136/esmoopen-2016-000097","title":"ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016","year":2016,"lang":"en","type":"review","venue":"ESMO Open","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":130,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"","keywords":"Curriculum; Medicine; Medical education; Oncology; Clinical Oncology; Internal medicine; Medical physics; Cancer; Psychology","retraction":null,"screen_n_in":null,"score":{"opus":0.09685524511029993,"gpt":0.4029989969889585,"spread":0.3061437518786586,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.001698102,0.0003731822,0.002394667,0.00022932,0.0001144449,0.0001435592,0.001317252,0.0008950274,0.004535994],"category_scores_gemma":[0.0007221687,0.0003433025,0.0004238824,0.0002515615,0.00009719766,0.0006623998,0.0003989674,0.0003393708,0.002454758],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00174816,"about_ca_system_score_gemma":0.001206109,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00234563,"about_ca_topic_score_gemma":0.002035061,"domain_scores_codex":[0.9968417,0.00006208035,0.001720076,0.0007750875,0.00003990443,0.0005611478],"domain_scores_gemma":[0.9978205,0.0002507011,0.00120181,0.000448704,0.00004482922,0.0002334675],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000006509008,0.0001090597,0.0001035758,0.0003119702,0.00006257345,0.000003990302,0.0000113026,5.755538e-8,1.122566e-10,0.1488987,0.1515834,0.6989089],"study_design_scores_gemma":[0.00100554,0.0001165596,0.00009333347,0.004031923,0.00002870624,0.00001615907,0.000006907343,0.00001062392,1.591428e-8,0.04125814,0.9529976,0.0004344727],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000001265902,0.8446154,0.002155945,0.005575435,0.003932466,0.002110203,0.002855742,0.0000239869,0.1387296],"genre_scores_gemma":[0.00001090741,0.9926831,0.0007196202,0.0007623716,0.001223549,0.001349609,0.0005245503,0.00004953499,0.002676754],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8014142,"threshold_uncertainty_score":0.9999019,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4290993146","doi":"10.1016/j.esmoop.2022.100553","title":"Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer","year":2022,"lang":"en","type":"review","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"Lilly Deutschland; Merck Sharp and Dohme; Eisai; Clovis Oncology; Boehringer Ingelheim; Ariad Pharmaceuticals; Roche; Daiichi-Sankyo; Teva Pharmaceutical Industries; Novartis; Merck; Sanofi-Aventis Deutschland; Pfizer; Queen Mary University of London; Bristol-Myers Squibb; AstraZeneca; Gilead Sciences","keywords":"Medicine; Breast cancer; Trastuzumab; Internal medicine; Pneumonitis; Nausea; Context (archaeology); Neutropenia; Oncology; Metastatic breast cancer; Cancer; Chemotherapy; Lung","retraction":null,"screen_n_in":null,"score":{"opus":0.3380420165733111,"gpt":0.5932876732972931,"spread":0.2552456567239821,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002458106,0.0003377872,0.002812876,0.0002626626,0.00004135132,0.00002392386,0.0008752805,0.0001769229,0.004629404],"category_scores_gemma":[0.0001090413,0.0002690715,0.0004559297,0.0007494318,0.0001146076,0.0001028073,0.0009208563,0.0007353676,0.0000157712],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002138154,"about_ca_system_score_gemma":0.00245074,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01186452,"about_ca_topic_score_gemma":0.0003988281,"domain_scores_codex":[0.9956962,0.0008122235,0.001702194,0.0006552492,0.0007540502,0.0003800311],"domain_scores_gemma":[0.9973365,0.0006869261,0.0007745457,0.0009471959,0.00008995891,0.0001648552],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003115443,0.001241117,0.0001032527,0.01518511,0.001460196,0.0005411782,0.0001658602,0.000008033049,1.997642e-8,0.00006925586,0.0006479766,0.9802665],"study_design_scores_gemma":[0.00188507,0.0007439989,0.0004386806,0.01976031,0.001989349,0.000134647,0.0004294974,0.000004939666,0.000001049353,0.00000301745,0.9744275,0.0001819423],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00001432475,0.9530732,0.000005267023,0.0004622609,0.0002583239,0.005366974,0.0002337857,0.00001009536,0.04057577],"genre_scores_gemma":[0.00003649796,0.9909278,0.004930607,0.00005577772,0.0001000559,0.001921201,0.00009167146,0.00008297277,0.001853478],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9800845,"threshold_uncertainty_score":0.9999762,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2748599797","doi":"10.1136/esmoopen-2017-000219","title":"Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer","year":2017,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre","funders":"Cancer Research UK; Pfizer","keywords":"Crizotinib; Medicine; Internal medicine; Lung cancer; Tolerability; Anaplastic lymphoma kinase; Response Evaluation Criteria in Solid Tumors; ALK inhibitor; Oncology; Adverse effect; Population; Clinical trial; Phases of clinical research","retraction":null,"screen_n_in":null,"score":{"opus":0.01645718667427923,"gpt":0.3405032469563614,"spread":0.3240460602820821,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000166171,0.0001289667,0.0003312218,0.00004000974,0.0001690803,0.00002214004,0.0001945634,0.00003208886,0.00004569193],"category_scores_gemma":[0.0001126099,0.00007848868,0.00003685164,0.00008593842,0.00009218676,0.0001568081,0.0001268145,0.00009209178,6.441049e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000904625,"about_ca_system_score_gemma":0.0003439458,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002087255,"about_ca_topic_score_gemma":0.001682666,"domain_scores_codex":[0.9989955,0.00005682264,0.0003430849,0.0002493375,0.0001949672,0.000160237],"domain_scores_gemma":[0.9988567,0.0001020541,0.0004463456,0.0003239846,0.0002187887,0.00005209096],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1252314,0.005287411,0.8436404,0.0003507055,0.0005701707,0.00001405918,0.0091736,0.0002522252,0.0001128565,0.0000367297,0.0006200942,0.0147104],"study_design_scores_gemma":[0.1741877,0.0009157588,0.8215082,0.0007864808,0.0003376156,6.313075e-7,0.00009272445,0.0002603823,0.001697717,0.000003037534,0.0001344675,0.0000752894],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9867952,0.00004745257,0.00001468599,0.0003068407,0.00006675284,0.005646082,0.0007844584,0.000003404273,0.006335129],"genre_scores_gemma":[0.9954538,0.00002644027,0.001745428,0.00003139494,0.00001725955,0.0002825166,0.0002211266,0.0000148187,0.00220719],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04895639,"threshold_uncertainty_score":0.3200675,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3004867668","doi":"10.1136/esmoopen-2019-000573","title":"New pathways in immune stimulation: targeting OX40","year":2020,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Immune system; Immune checkpoint; Cytotoxic T cell; Immunotherapy; Immunology; Medicine; Antigen; Cancer research; Biology; In vitro","retraction":null,"screen_n_in":null,"score":{"opus":0.05062891018030245,"gpt":0.3050087894665851,"spread":0.2543798792862826,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001704851,0.00007642704,0.0001854214,0.00002323123,0.00003458522,0.00003855595,0.0001622371,0.00004290463,0.002482469],"category_scores_gemma":[0.00004906616,0.00006766604,0.00004516254,0.0002305522,0.00001173766,0.0001188801,0.0000914724,0.0001110216,0.00007685359],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004328685,"about_ca_system_score_gemma":0.0001522207,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002259689,"about_ca_topic_score_gemma":0.0000503785,"domain_scores_codex":[0.9993626,0.00002183587,0.000222109,0.0001629368,0.0001037255,0.0001267268],"domain_scores_gemma":[0.9997125,0.00002167069,0.00004619066,0.0001234114,0.00001570002,0.00008047964],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.01738738,0.0002994525,0.1631276,0.0002122824,0.0003871568,0.0004902046,0.01581513,0.0003341249,0.1789043,0.001044385,0.1418522,0.4801458],"study_design_scores_gemma":[0.013385,0.0006278749,0.5781092,0.0002604735,0.00003393664,0.00001307925,0.0006735247,0.001663148,0.01994626,0.0002021034,0.3847536,0.0003318127],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.826125,0.003942144,0.001769919,0.06728149,0.0007001054,0.00310771,0.0000124376,0.0001930348,0.09686811],"genre_scores_gemma":[0.9928302,0.00004552086,0.003028411,0.002987568,0.0002029992,0.000008509221,0.00003861649,0.00001488698,0.0008433266],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4798139,"threshold_uncertainty_score":0.9984294,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4391506607","doi":"10.1016/j.esmoop.2023.102226","title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Bayer Yakuhin; Sierra Oncology; Eli Lilly Japan; Pfizer Japan; Novartis Pharma; INCLIVA Instituto de Investigación Sanitaria; Ipsen; Teijin Pharma; Japanese Society of Medical Oncology; Otsuka Pharmaceutical; Daiichi Sankyo Europe; Veracyte; European Society for Medical Oncology; Chugai Pharmaceutical; Vifor Pharma; Natera; Daiichi-Sankyo; MacroGenics; AstraZeneca; Genentech; Sysmex Corporation; Astellas Pharma; Eisai; FibroGen; Fondazione Beretta; BeiGene; Mirati Therapeutics; Hellenic Society of Medical Oncology; Pharmacyclics; Exelixis; Kissei; Pfizer; American Association for Cancer Research; Servier; Incyte; JST-Mirai Program; Astellas Foundation for Research on Metabolic Disorders; Gilead Sciences; Taiho Pharmaceutical; Boehringer Ingelheim Japan; Merck KGaA; Sanofi; Amgen; Bristol-Myers Squibb; Ono Pharmaceutical; Eli Lilly and Company; SymBio Pharmaceuticals Limited; American Society of Clinical Oncology; Foundation Medicine; GlaxoSmithKline; Seagen; Relay Therapeutics","keywords":"Medicine; Cancer; Clinical Practice; Intensive care medicine; Internal medicine; Oncology; Family medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1231281084762858,"gpt":0.4420520611936647,"spread":0.3189239527173789,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003719024,0.0001507243,0.0003480564,0.0000567639,0.00006917728,0.00007678325,0.0001530605,0.00004065164,0.000126579],"category_scores_gemma":[0.0005809834,0.00007750784,0.00009329642,0.000235121,0.0000525979,0.0001756203,0.0001108061,0.0000769384,0.000003394733],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006757099,"about_ca_system_score_gemma":0.0001774061,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003759044,"about_ca_topic_score_gemma":0.001355485,"domain_scores_codex":[0.9989087,0.00003248467,0.0004044152,0.0002921245,0.0001934491,0.0001688197],"domain_scores_gemma":[0.9985878,0.0006175149,0.0001272353,0.000264678,0.0003342038,0.00006856331],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001182192,0.0001960553,0.4440404,0.00006566556,0.0009936272,0.00001017837,0.0001709559,0.00000308708,9.751032e-8,0.000134851,0.09527354,0.4579293],"study_design_scores_gemma":[0.004649275,0.001130443,0.4701901,0.0001558128,0.001446676,0.000001920401,0.000320193,0.0001110238,0.000006834371,0.00001137162,0.5219094,0.00006699208],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5723149,0.02098374,0.002326317,0.3604773,0.006161739,0.02608119,0.0005964942,0.000246526,0.01081185],"genre_scores_gemma":[0.9639586,0.009921649,0.009386094,0.004467464,0.00059465,0.00186124,0.0001225121,0.00006403832,0.009623772],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4578623,"threshold_uncertainty_score":0.5682575,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3080424252","doi":"10.1136/esmoopen-2020-000714","title":"Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial","year":2020,"lang":"en","type":"article","venue":"ESMO Open","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Cancer Research UK; Exelixis","keywords":"Sorafenib; Cabozantinib; Medicine; Placebo; Hepatocellular carcinoma; Internal medicine; Clinical endpoint; Subgroup analysis; Population; Oncology; Gastroenterology; Randomized controlled trial; Surgery; Confidence interval; Cancer; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.1231581948242682,"gpt":0.3314540554563082,"spread":0.20829586063204,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002063525,0.0003548671,0.00117502,0.00009998066,0.0001217737,0.00005172817,0.0003592294,0.0001341244,0.001325668],"category_scores_gemma":[0.00008158619,0.0002336477,0.0010151,0.0008677774,0.00008414564,0.000126747,0.0001596702,0.0001166044,0.00001429999],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008490078,"about_ca_system_score_gemma":0.0003031156,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004649005,"about_ca_topic_score_gemma":0.0003362565,"domain_scores_codex":[0.9980029,0.000126406,0.0006326421,0.0005970626,0.000275388,0.0003655924],"domain_scores_gemma":[0.9985774,0.0001225361,0.0002603188,0.0006258692,0.0001375006,0.0002763865],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1647628,0.00307052,0.8110527,0.0001732776,0.00494348,0.0003679446,0.002466581,0.000009241274,0.005622688,0.0001058478,0.0004256289,0.006999331],"study_design_scores_gemma":[0.4860751,0.02044323,0.04007214,0.00008860758,0.0299062,0.00001342228,0.0002983696,0.04840893,0.3074965,0.0000376859,0.06627652,0.0008833124],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9899057,0.0003336004,0.0002299498,0.001685341,0.000168257,0.006662827,0.0005599596,0.00003067593,0.0004237508],"genre_scores_gemma":[0.9954584,0.00001588236,0.0008134579,0.0004639267,0.0002739936,0.00137632,0.0006433483,0.00004837589,0.0009063557],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7709805,"threshold_uncertainty_score":0.9995872,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4388840640","doi":"10.1016/j.esmoop.2023.102047","title":"Insomnia in adult patients with cancer: ESMO Clinical Practice Guideline","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Sleep and related disorders","field":"Psychology","cited_by":82,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"European Society for Medical Oncology","keywords":"Insomnia; Guideline; Medicine; Clinical Practice; First line therapy; Population; Chronic insomnia; Intensive care medicine; Psychiatry; Family medicine; Oncology; Sleep disorder; Pathology; Environmental health","retraction":null,"screen_n_in":null,"score":{"opus":0.03309259223051882,"gpt":0.4296957238549652,"spread":0.3966031316244464,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000672049,0.0001418125,0.0002478534,0.0001075479,0.00006659154,0.0000415791,0.000515083,0.0002308116,0.001827629],"category_scores_gemma":[0.0004788392,0.0001094811,0.00003846547,0.0007040482,0.00007060618,0.0002419903,0.0002039794,0.0004414857,0.002297184],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003041327,"about_ca_system_score_gemma":0.00009166892,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02260403,"about_ca_topic_score_gemma":0.004196866,"domain_scores_codex":[0.9981748,0.000262406,0.0005817382,0.0004413362,0.00020152,0.000338235],"domain_scores_gemma":[0.9988337,0.0002695921,0.0001841299,0.0004162975,0.00020205,0.00009426016],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001027932,0.0009896697,0.5103289,0.00000271807,0.0003881782,0.0001092829,0.001152647,0.0001082108,5.157833e-8,0.0007700112,0.4195771,0.06554534],"study_design_scores_gemma":[0.009422277,0.0002613964,0.4614598,0.00004842981,0.00008499531,0.000001893507,0.001240577,0.00008508898,7.174344e-7,0.00009902627,0.5270832,0.0002126644],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7389438,0.00008956427,0.00002050468,0.01291514,0.002673398,0.001313015,0.00003036973,0.0001365837,0.2438776],"genre_scores_gemma":[0.9411051,0.0012959,0.00337965,0.03469228,0.000451682,0.0007668667,0.0006924209,0.0001932666,0.01742282],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2264548,"threshold_uncertainty_score":0.9990848,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4385651875","doi":"10.1016/j.esmoop.2023.101615","title":"Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Jewish General Hospital","funders":"AstraZeneca","keywords":"Concordance; Medicine; Immunohistochemistry; Internal medicine; Trastuzumab; Oncology; Breast cancer; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.09067429760705649,"gpt":0.4811611636940519,"spread":0.3904868660869954,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001369772,0.0001506393,0.0004316645,0.00003896408,0.0001790782,0.00008697207,0.0003845548,0.00004074793,0.0003013985],"category_scores_gemma":[0.0005466877,0.00007292703,0.00003109733,0.0002706452,0.0002638711,0.00006476301,0.000731021,0.0002397979,0.00003499728],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001145216,"about_ca_system_score_gemma":0.0001038879,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002189056,"about_ca_topic_score_gemma":0.0005560881,"domain_scores_codex":[0.9984415,0.0002556448,0.0002749724,0.0004077369,0.000352972,0.0002671317],"domain_scores_gemma":[0.9989496,0.0002119146,0.00008527408,0.0004875368,0.0001411295,0.0001244891],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0003215124,0.0002200751,0.9865823,0.00005429358,0.00009016888,0.00006494735,0.002567471,5.010792e-7,0.00002676117,0.00001318169,0.0005936406,0.009465175],"study_design_scores_gemma":[0.000982305,0.0008009247,0.9968019,0.0001659443,0.0001271522,0.00002831752,0.0007740252,0.00003518579,0.0000317454,0.00005154724,0.0001251524,0.00007581044],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9872819,0.00005670283,8.257934e-7,0.009057585,0.0001156924,0.002871345,0.0002222766,0.00002441749,0.0003692833],"genre_scores_gemma":[0.9950495,0.0007009502,0.00005345648,0.0003117202,0.00004553047,0.0004416371,0.000004067203,0.00001995783,0.003373227],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01021962,"threshold_uncertainty_score":0.3309213,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4399361815","doi":"10.1016/j.esmoop.2024.103488","title":"An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"National Cancer Institute; AstraZeneca; Incyte; Amgen","keywords":"Medicine; Cohort; Clinical endpoint; Internal medicine; Oncology; Adverse effect; Progression-free survival; Retrospective cohort study; Surgery; Gastroenterology; Overall survival; Clinical trial","retraction":null,"screen_n_in":null,"score":{"opus":0.1468446751598439,"gpt":0.404070658401311,"spread":0.2572259832414672,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005332672,0.0002325377,0.0006450528,0.000153407,0.000079584,0.0002538424,0.0009351483,0.00008164232,0.0002202353],"category_scores_gemma":[0.00009611143,0.0001923529,0.00003974314,0.0005137442,0.00004899605,0.0004849249,0.0008360172,0.0003548837,0.00006320512],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009343821,"about_ca_system_score_gemma":0.0002350213,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.03705204,"about_ca_topic_score_gemma":0.0107454,"domain_scores_codex":[0.9979427,0.0001167364,0.0005883256,0.0007538306,0.0003222925,0.0002761076],"domain_scores_gemma":[0.9987513,0.0001665254,0.00008572613,0.0007912379,0.00007664948,0.0001285505],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.009785416,0.01539023,0.7019711,0.0002738402,0.001504962,0.004499205,0.09666254,0.00001212065,0.002629564,0.0004964137,0.1369279,0.0298468],"study_design_scores_gemma":[0.02084925,0.002871301,0.9636696,0.0005300326,0.0001989334,0.0000155442,0.004676637,0.0002602822,0.0006281048,0.0001967778,0.005844364,0.0002591746],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.972147,0.001073388,0.000001653374,0.001522153,0.0003123394,0.001836464,0.0001935332,0.00004450273,0.0228689],"genre_scores_gemma":[0.9964737,0.00002763745,0.000482002,0.0003137521,0.0002196389,0.0001631737,0.0002341894,0.00003899418,0.002046952],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2616985,"threshold_uncertainty_score":0.9693603,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4377966316","doi":"10.1016/j.esmoop.2023.101558","title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Eli Lilly Japan; Chugai Pharmaceutical; Pfizer Japan; Genentech; Foundation Medicine; Sierra Oncology; Daiichi Sankyo Europe; Servier; FibroGen; Astellas Pharma; Eisai; Daiichi-Sankyo; European Society for Medical Oncology; Monash University; Natera; Seagen; Pfizer; Incyte; Azərbaycan Milli Elmlər Akademiyası; Boehringer Ingelheim Japan; Ipsen; Japanese Society of Medical Oncology; BeiGene; Sanofi; Amgen; Les Laboratories Pierre Fabre; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Colorectal cancer; Medicine; Clinical Practice; Oncology; Internal medicine; Cancer; Family medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.160106472111819,"gpt":0.463078024038618,"spread":0.3029715519267989,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003466153,0.0001863958,0.000554433,0.00003646155,0.0001857333,0.0000314711,0.0001138265,0.00003477807,0.00005508249],"category_scores_gemma":[0.001165585,0.0000917168,0.00009727874,0.0002255556,0.0001123226,0.0001137157,0.0001269404,0.00005764373,0.000003551018],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008506796,"about_ca_system_score_gemma":0.0002145372,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006202138,"about_ca_topic_score_gemma":0.009128222,"domain_scores_codex":[0.9988036,0.00006067921,0.0004231697,0.0003066231,0.0002009743,0.0002049948],"domain_scores_gemma":[0.9976994,0.001153272,0.0002068134,0.0001918031,0.0006725634,0.00007608091],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01050189,0.0009400131,0.5974406,0.00004802877,0.004845253,0.00002486882,0.001515256,0.000006583319,0.000001009685,0.00006624473,0.03468269,0.3499276],"study_design_scores_gemma":[0.01263219,0.005545705,0.8379771,0.0001011139,0.002291058,0.000002742283,0.001782754,0.0000903022,0.00008663247,0.00002272279,0.1393507,0.0001169748],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9672406,0.001516218,0.0000118854,0.0241209,0.0004610729,0.005322005,0.0003711092,0.00003688105,0.0009193345],"genre_scores_gemma":[0.9854509,0.005708447,0.002295621,0.0009173648,0.0001007492,0.00414488,0.0001248716,0.00003418083,0.001223003],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3498106,"threshold_uncertainty_score":0.9375819,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4383162923","doi":"10.1016/j.esmoop.2023.101592","title":"Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis","year":2023,"lang":"en","type":"review","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Daiichi Sankyo Europe; Ipsen; Astellas Pharma; Eisai; Seagen; Gilead Sciences; Servier; Instituto de Salud Carlos III; Amgen; Pfizer; Celgene; Eli Lilly and Company; AstraZeneca; Oncolytics Biotech","keywords":"Medicine; Internal medicine; Oncology; Hazard ratio; Breast cancer; Confidence interval; Meta-analysis; Odds ratio; Hormone receptor; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.2672753327176868,"gpt":0.5170282764841014,"spread":0.2497529437664146,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003784831,0.0005213364,0.01693277,0.000688976,0.0000337031,0.00008454538,0.0008590144,0.0002149466,0.001852376],"category_scores_gemma":[0.0009395924,0.0003276467,0.001526373,0.003994373,0.0001057799,0.00008127125,0.0006873399,0.0006599649,0.0001240718],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004559722,"about_ca_system_score_gemma":0.002070792,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01963092,"about_ca_topic_score_gemma":0.002203852,"domain_scores_codex":[0.9941734,0.001515152,0.002053766,0.0008014118,0.0008902036,0.0005660724],"domain_scores_gemma":[0.996442,0.0008015189,0.0008365086,0.001361431,0.0002488322,0.0003096988],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.000004565916,0.00006147973,0.0001125944,0.8969023,0.09879481,0.0001026668,0.00003685433,7.864617e-7,3.790208e-9,0.00002331366,0.0007256079,0.003235066],"study_design_scores_gemma":[0.0001468897,0.00003835119,0.0001177807,0.3499286,0.6304096,0.0000548227,0.00001269571,0.000007476841,4.238959e-8,0.000005460932,0.0190808,0.0001975228],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[8.053806e-7,0.9800712,9.497492e-7,0.0008372303,0.00002678185,0.01769772,0.0009047352,0.00002194158,0.0004386485],"genre_scores_gemma":[0.000008339712,0.9859412,0.00008146412,0.0002223915,0.00002280868,0.0101261,0.0001608183,0.0001085152,0.003328363],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.5469737,"threshold_uncertainty_score":0.9999176,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3211466869","doi":"10.1016/j.esmoop.2021.100292","title":"Distribution of the workforce involved in cancer care: a systematic review of the literature","year":2021,"lang":"en","type":"review","venue":"ESMO Open","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University","funders":"Istituto Nazionale Tumori IRCCS \"Fondazione G. Pascale\"; European Society for Medical Oncology; Daiichi-Sankyo; Università degli Studi di Milano-Bicocca; World Health Organization","keywords":"Workforce; Systematic review; Cancer; Distribution (mathematics); Medicine; MEDLINE; Political science; Economics; Mathematics; Internal medicine; Economic growth","retraction":null,"screen_n_in":null,"score":{"opus":0.03988454844191102,"gpt":0.4428152606643342,"spread":0.4029307122224232,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004711542,0.0001967712,0.002717583,0.0000180466,0.00004160607,0.000007947434,0.0007749676,0.0002609418,0.00005538009],"category_scores_gemma":[0.0005150091,0.00008114275,0.000476099,0.0009340987,0.0001207074,0.00004032456,0.0002127769,0.0005487851,5.627609e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003767237,"about_ca_system_score_gemma":0.0009152042,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000499357,"about_ca_topic_score_gemma":0.0001060567,"domain_scores_codex":[0.9979571,0.0007616364,0.0007821216,0.000199126,0.0001869923,0.0001130094],"domain_scores_gemma":[0.9978719,0.0002076056,0.0008531435,0.0008961672,0.0001502608,0.00002090787],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.00000506064,0.00003458666,0.00008893093,0.9768339,0.0001576869,0.000005785922,0.0001925799,3.364405e-7,3.201886e-8,0.0003755915,0.001155848,0.02114965],"study_design_scores_gemma":[0.0001327639,0.0000131412,0.00002258064,0.6183646,0.0009020349,0.00002062339,0.00002270017,1.030302e-7,0.000001492261,0.000006166545,0.3804667,0.00004700045],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000002394235,0.9929581,0.000003958227,0.0003544247,0.0005194846,0.005641001,0.0001213867,0.000002322015,0.0003969649],"genre_scores_gemma":[0.00001812729,0.9972136,0.00003051445,0.0005807126,0.00007771272,0.0006400412,0.0001604715,0.00001663394,0.001262179],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.3793109,"threshold_uncertainty_score":0.3308905,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2571465553","doi":"10.1136/esmoopen-2016-000127","title":"The European Cancer Patient’s Bill of Rights, update and implementation 2016","year":2016,"lang":"en","type":"review","venue":"ESMO Open","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":73,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"University of Leeds; National Institute for Health and Care Research; Francis Crick Institute","keywords":"Bill of rights; Political science; Law; Human rights","retraction":null,"screen_n_in":null,"score":{"opus":0.05318769051880295,"gpt":0.3279169812812142,"spread":0.2747292907624112,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000832267,0.0002537679,0.001059941,0.00009993854,0.0001977526,0.0001904496,0.0007165099,0.00008869344,0.0008043029],"category_scores_gemma":[0.00002340141,0.000143253,0.0001636914,0.00008534339,0.0001155496,0.0003963412,0.0004180318,0.0001183935,0.0006001157],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001360998,"about_ca_system_score_gemma":0.000111547,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.009365267,"about_ca_topic_score_gemma":0.001082004,"domain_scores_codex":[0.9980888,0.0000671123,0.001124549,0.000412946,0.00002333739,0.0002832101],"domain_scores_gemma":[0.9978033,0.00007891134,0.001564485,0.0004444317,0.00003104937,0.00007778642],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000003664097,0.000007024531,0.00007818523,0.000155092,0.0001126666,7.375023e-7,0.00003997258,3.615394e-8,4.658236e-9,0.03811888,0.02004502,0.9414387],"study_design_scores_gemma":[0.0002645538,0.00003488339,0.0002931668,0.001116388,0.00003416872,0.000001392468,0.000006292803,2.382843e-7,8.946735e-7,0.01759678,0.9804014,0.0002498269],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00001726174,0.9509533,0.00001962403,0.0002892838,0.0006239195,0.000862768,0.001551502,0.00000689531,0.04567546],"genre_scores_gemma":[0.0002298021,0.9978982,0.00004182837,0.00008946314,0.0001906825,0.0001127235,0.00004299903,0.00004679319,0.001347513],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9603564,"threshold_uncertainty_score":0.9972315,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3154880036","doi":"10.1016/j.esmoop.2021.100117","title":"Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring","year":2021,"lang":"en","type":"review","venue":"ESMO Open","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":71,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University","funders":"Cilag; Foundation Medicine; Chugai Pharmaceutical; Novartis Farmacéutica; European Society for Medical Oncology; Shire; Eisai; Seagen; G1 Therapeutics; Genentech; Veracyte; SkylineDx; Roche; Nordic Nanovector; Meso Scale Diagnostics; Les Laboratories Pierre Fabre; Celldex Therapeutics; Ipsen; Array BioPharma; Merck KGaA; Taiho Pharmaceutical; F. Hoffmann-La Roche; Amgen; Boehringer Ingelheim; Radius Health; Daiichi Sankyo Europe; Servier; Bayer; Gilead Sciences; NeraCare; Cancer Research UK; World Health Organization; Sanofi; Novartis; Ariad Pharmaceuticals; Pfizer; AstraZeneca; Eli Lilly and Company; Samsung; Bristol-Myers Squibb","keywords":"Medicine; Clinical trial; Scale (ratio); Food and drug administration; Agency (philosophy); Clinical study design; Medical physics; Research design; Risk analysis (engineering); Pathology; Statistics","retraction":null,"screen_n_in":null,"score":{"opus":0.5438960934358554,"gpt":0.5372332370321362,"spread":0.00666285640371922,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009654704,0.0004237222,0.005537518,0.0003717436,0.0001210763,0.0002302106,0.001781346,0.0003135554,0.0003118125],"category_scores_gemma":[0.001023781,0.0003754707,0.0004876948,0.0006468468,0.0002974563,0.0007009659,0.0021198,0.0005065448,0.00000817981],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005622031,"about_ca_system_score_gemma":0.0003340007,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.01299063,"about_ca_topic_score_gemma":0.0235644,"domain_scores_codex":[0.9930859,0.0002359476,0.004787419,0.001424472,0.00009607363,0.0003701458],"domain_scores_gemma":[0.9922962,0.002461151,0.003270358,0.001718962,0.00008338685,0.0001699075],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00003146427,0.0003112285,0.7277645,0.0002809039,0.001407278,0.000004823977,0.0001451655,0.00002104453,1.005577e-9,0.001099552,0.0002532838,0.2686807],"study_design_scores_gemma":[0.00154913,0.0002734257,0.8054482,0.0008715961,0.001896804,0.000003445972,0.0006417041,0.0001121363,3.28913e-7,0.0003133086,0.1883831,0.0005068765],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.09517311,0.8981757,0.0002577992,0.00008507785,0.0006763173,0.002432444,0.002238571,0.000007954501,0.0009529911],"genre_scores_gemma":[0.05499976,0.9429012,0.00104517,0.00005409203,0.0002022053,0.0001181503,0.0004851521,0.00005143188,0.0001428217],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.2681738,"threshold_uncertainty_score":0.9998697,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4319301760","doi":"10.1016/j.esmoop.2022.100744","title":"Cancer burden in adolescents and young adults in Europe","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; McMaster Children's Hospital","funders":"European Society for Medical Oncology","keywords":"Medicine; Overdiagnosis; European union; Incidence (geometry); Cancer; Population; Public health; Thyroid cancer; Young adult; Epidemiology; Demography; Environmental health; Gerontology; Internal medicine; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.03520839912292764,"gpt":0.3470547380021982,"spread":0.3118463388792706,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005485585,0.0001177748,0.0003084769,0.0001519571,0.00002610285,0.00004026526,0.0002265801,0.00005487418,0.0000919891],"category_scores_gemma":[0.0002051029,0.0001164868,0.0000162726,0.0007803129,0.00003456212,0.0001399033,0.0003680348,0.0002300842,0.0001303718],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007071638,"about_ca_system_score_gemma":0.0001386699,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.1156119,"about_ca_topic_score_gemma":0.09202,"domain_scores_codex":[0.998782,0.00009562163,0.0002864387,0.0003420319,0.0002259178,0.0002680365],"domain_scores_gemma":[0.9995248,0.00002136213,0.00005003362,0.0002531985,0.0000419595,0.0001086094],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0003456217,0.00006690516,0.980143,0.0002057204,0.0000133443,0.0001855584,0.007365094,0.000009426029,0.00002787145,0.00002403197,0.003775832,0.007837657],"study_design_scores_gemma":[0.003652682,0.00005383303,0.986326,0.002637711,0.000007807478,0.000007276321,0.0008030326,0.0001638716,0.00005232687,0.00002928188,0.006135518,0.0001306757],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9873415,0.0002299707,4.572171e-7,0.00718191,0.0002816433,0.0007509365,0.000009916626,0.00004263293,0.004161051],"genre_scores_gemma":[0.9961799,0.0004764995,0.00002945062,0.001210631,0.0001747164,0.00006008173,0.00001788631,0.00002887179,0.001822012],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0235919,"threshold_uncertainty_score":0.9245483,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4405475772","doi":"10.1016/j.esmoop.2024.104003","title":"ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; Servier; European Society for Medical Oncology; Kasturba Medical College, Manipal; Incyte; Eisai; Ipsen; BeiGene; Merck KGaA; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Interim; Biliary tract cancer; Guideline; Biliary tract; Medicine; Clinical Practice; Interim analysis; Cancer; Internal medicine; General surgery; Clinical trial; Family medicine; Pathology; Geography","retraction":null,"screen_n_in":null,"score":{"opus":0.1061749759012404,"gpt":0.4643638996670465,"spread":0.3581889237658061,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001186776,0.0001426559,0.0003188073,0.00004220292,0.00005643902,0.00006381802,0.0003404855,0.00004770216,0.001051844],"category_scores_gemma":[0.00008989013,0.00008282236,0.0001464096,0.0001966354,0.00009078407,0.0001506342,0.0004042216,0.0003133793,0.0001524501],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006115807,"about_ca_system_score_gemma":0.000105943,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001196753,"about_ca_topic_score_gemma":0.00008738496,"domain_scores_codex":[0.998603,0.00008518066,0.000541651,0.0003474457,0.0002584046,0.0001643333],"domain_scores_gemma":[0.9989955,0.0002693785,0.00009312155,0.0004851282,0.00009790804,0.00005894856],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0008173311,0.0004595424,0.004565901,0.0002354932,0.00216762,0.0006881458,0.0005684803,0.000003372624,0.00001162068,0.005788275,0.8373562,0.147338],"study_design_scores_gemma":[0.0006714359,0.0002992379,0.06583077,0.000735026,0.0006398793,0.00002792312,0.0008872058,0.0001002635,0.0002108341,0.000136059,0.9303597,0.0001016472],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"empirical","genre_scores_codex":[0.1044565,0.01049794,0.0002108524,0.4135188,0.003874354,0.002975217,0.00009521672,0.0001371514,0.464234],"genre_scores_gemma":[0.9671605,0.005142982,0.002506039,0.01924639,0.0005433171,0.0001763074,0.00002902981,0.00003895647,0.005156499],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.862704,"threshold_uncertainty_score":0.9998614,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4385173573","doi":"10.1016/j.esmoop.2023.101613","title":"Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis","year":2023,"lang":"en","type":"review","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Daiichi Sankyo Europe; Daiichi-Sankyo","keywords":"Medicine; Internal medicine; Breast cancer; Incidence (geometry); Asymptomatic; Cardiotoxicity; Oncology; Gastroenterology; Lung cancer; Cancer; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.1500703787125109,"gpt":0.4438841884306995,"spread":0.2938138097181886,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001536698,0.0004884822,0.009260753,0.0005113717,0.00004755442,0.00009828954,0.0005498654,0.0001155522,0.0002795968],"category_scores_gemma":[0.0004539204,0.0003024158,0.0007333579,0.001857081,0.0002155083,0.0001597599,0.0006200779,0.0004682794,0.000003700242],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007633747,"about_ca_system_score_gemma":0.00105442,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007439215,"about_ca_topic_score_gemma":0.004370385,"domain_scores_codex":[0.9958746,0.0008863678,0.001298783,0.0008014793,0.000793695,0.0003450147],"domain_scores_gemma":[0.9975537,0.0003323254,0.0006376227,0.0008124989,0.0002810542,0.0003828059],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.00006140503,0.0001651747,0.0009108498,0.9314702,0.06333018,0.0001253478,0.00008519596,8.751804e-7,1.292063e-8,0.000003033876,0.0001217718,0.003725997],"study_design_scores_gemma":[0.0003847027,0.0001642098,0.0006809692,0.4120841,0.5857162,0.00003826848,0.00002240574,0.00001523071,1.339316e-7,0.000002105176,0.0006117361,0.0002799637],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00005011231,0.9883792,0.0000126554,0.0002295046,0.00002013535,0.01027695,0.0009359617,0.00001412161,0.00008132784],"genre_scores_gemma":[0.003054704,0.9928483,0.00003766183,0.0001462236,0.00002238746,0.003547759,0.0001005194,0.00007252338,0.0001699444],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.522386,"threshold_uncertainty_score":0.9999428,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4210298192","doi":"10.1016/j.esmoop.2022.100403","title":"Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Cilag; Janssen Pharmaceuticals; Chugai Pharmaceutical; AstraZeneca; Genentech; MorphoSys; PharmaMar; Daiichi Sankyo Europe; European Society for Medical Oncology; Deutsche Krebshilfe; Pfizer; José Carreras Leukämie-Stiftung; Shionogi; British Society for Haematology; National Institute for Health and Care Research; Bayer; Astellas Pharma; Celltrion; SkylineDx; Sanofi-Aventis Deutschland; BeiGene; Sanofi; TG Therapeutics; Medac; Ipsen; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; Meso Scale Diagnostics; Helsinn; Takeda Pharmaceutical Company; Novartis Pharma; AbbVie; AOP Orphan; Bundesministerium für Bildung und Forschung; EUSA Pharma; Merck KGaA; Incyte; Servier; Gilead Sciences; Celgene; Novartis; GlaxoSmithKline; Eli Lilly and Company; Bristol-Myers Squibb; Deutsche Forschungsgemeinschaft; Roche; Sierra Oncology; Galecto; Astellas Pharma US; Boehringer Ingelheim; Amgen","keywords":"Pandemic; Coronavirus disease 2019 (COVID-19); Medicine; Consensus conference; MEDLINE; Family medicine; 2019-20 coronavirus outbreak; Intensive care medicine; Political science; Internal medicine; Pathology; Disease; Law","retraction":null,"screen_n_in":null,"score":{"opus":0.1554210049298026,"gpt":0.4771415186154561,"spread":0.3217205136856536,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006152854,0.0001947354,0.0003920857,0.00009335663,0.001288801,0.00006674205,0.0005852773,0.00006747458,0.00229832],"category_scores_gemma":[0.0002302104,0.0001348664,0.00007988198,0.0002218772,0.0001209721,0.00009673004,0.002469257,0.0005615101,0.0000158968],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001046073,"about_ca_system_score_gemma":0.0006248655,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01100427,"about_ca_topic_score_gemma":0.002324363,"domain_scores_codex":[0.9980015,0.0003147658,0.0003610058,0.0004712071,0.000392197,0.0004593573],"domain_scores_gemma":[0.998515,0.0002637984,0.0001373619,0.0005267389,0.00005275997,0.0005044042],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002129903,0.0004830706,0.9539415,0.0002344479,0.00009402388,0.0007079642,0.0144649,0.0001389011,0.00008057916,0.0001645544,0.02162764,0.005932463],"study_design_scores_gemma":[0.007355665,0.001287555,0.8097555,0.0001628106,0.00008614488,0.001142728,0.01230731,0.0005396631,0.0001071502,0.001483157,0.1652116,0.0005606965],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.928919,0.0002246009,0.0000119956,0.06756864,0.0004114483,0.00133663,0.00004384316,0.0001118326,0.001372032],"genre_scores_gemma":[0.9645471,0.00006662672,0.00005087146,0.03376514,0.0001301277,0.0004023339,0.0000560991,0.00003010891,0.0009515836],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1441861,"threshold_uncertainty_score":0.9986137,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2808864948","doi":"10.1136/esmoopen-2018-000361","title":"Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis","year":2018,"lang":"en","type":"review","venue":"ESMO Open","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Hôpital Charles-Le Moyne; Université de Sherbrooke","funders":"European Society for Medical Oncology; Genentech; GlaxoSmithKline; Teva Pharmaceutical Industries; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Discontinuation; Oncology; Metastatic breast cancer; Meta-analysis; Breast cancer; Adverse effect; Neutropenia; PARP inhibitor; Population; Cancer; Chemotherapy; Poly ADP ribose polymerase; Polymerase","retraction":null,"screen_n_in":null,"score":{"opus":0.1524902586108739,"gpt":0.4081192647699527,"spread":0.2556290061590788,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006861151,0.0007479239,0.01086509,0.0002060287,0.0001410872,0.00007904647,0.0003791688,0.0000925147,0.0008206913],"category_scores_gemma":[0.00006710648,0.0003220121,0.001920786,0.001122849,0.0002486686,0.0001084163,0.00006527189,0.0001115046,0.0000105661],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006298673,"about_ca_system_score_gemma":0.0003979042,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001215973,"about_ca_topic_score_gemma":0.0004810655,"domain_scores_codex":[0.9961606,0.0007028493,0.001632533,0.000701789,0.0005079358,0.0002942953],"domain_scores_gemma":[0.994891,0.0008855207,0.002322539,0.001070848,0.0006703654,0.000159761],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.0001378472,0.0007551246,0.00001573281,0.4923227,0.5001175,0.000004711516,0.0003317463,0.000001190933,9.933778e-9,0.000004994167,0.0009051742,0.005403313],"study_design_scores_gemma":[0.001611921,0.001082502,0.00001641806,0.06054107,0.8716587,0.00002005316,0.00003564479,0.000002675477,0.000005864021,0.000006758883,0.06472597,0.0002923729],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000006855327,0.966957,0.00005875233,0.0004935644,0.00005482446,0.02877623,0.003591416,0.0000157993,0.00004560911],"genre_scores_gemma":[0.00006587735,0.9792897,0.0005054284,0.0004098044,0.00004025306,0.01831573,0.0004773763,0.00009027163,0.0008055471],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.4317816,"threshold_uncertainty_score":0.9999232,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4321769995","doi":"10.1016/j.esmoop.2023.100787","title":"Immune-related adverse events as potential surrogates of immune checkpoint inhibitors’ efficacy: a systematic review and meta-analysis of randomized studies","year":2023,"lang":"en","type":"review","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Medicine; Adverse effect; Internal medicine; Hazard ratio; Randomized controlled trial; Confidence interval; Meta-analysis; Placebo; Odds ratio; Oncology; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.09677872305832615,"gpt":0.4066153583180608,"spread":0.3098366352597347,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.009674848,0.0007094877,0.03621712,0.0006862566,0.00007191623,0.00001411922,0.0006034514,0.000274778,0.0006655329],"category_scores_gemma":[0.00213537,0.0004039958,0.01365115,0.00217318,0.0003510334,0.00009390763,0.0005917647,0.0003136988,0.00003593342],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001124447,"about_ca_system_score_gemma":0.0002958527,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001626053,"about_ca_topic_score_gemma":0.00003187991,"domain_scores_codex":[0.9898801,0.002031846,0.00665911,0.0005749048,0.0005912466,0.0002627709],"domain_scores_gemma":[0.9918637,0.001200697,0.005321914,0.00115934,0.0003747735,0.00007956159],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.001817213,0.00009485661,1.482436e-7,0.4641848,0.5334083,0.00001316282,0.0001567434,3.965256e-7,0.000002770303,0.000006260276,0.00002086228,0.0002943972],"study_design_scores_gemma":[0.02014801,0.00009190605,0.000005838547,0.1985968,0.7801633,0.00003286905,0.0001169436,0.00000183863,0.00001887766,0.000009792481,0.00056191,0.0002519995],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00004684715,0.9830878,6.1685e-7,0.0002048192,0.0001528508,0.01626732,0.0001099379,0.00002869298,0.0001010574],"genre_scores_gemma":[0.0002861281,0.9938407,0.00003511849,0.00003791795,0.00000961248,0.001364793,0.0003334478,0.00007473068,0.004017572],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.2655881,"threshold_uncertainty_score":0.9998412,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2528890271","doi":"10.1136/esmoopen-2016-000077","title":"Interventions to improve care coordination between primary healthcare and oncology care providers: a systematic review","year":2016,"lang":"en","type":"review","venue":"ESMO Open","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Dalhousie University; University of Toronto; McMaster University; Queen's University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Psychological intervention; CINAHL; Systematic review; MEDLINE; Health care; Cochrane Library; Randomized controlled trial; Family medicine; Meta-analysis; Oncology; Intensive care medicine; Nursing; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1949507299562116,"gpt":0.4935361624290979,"spread":0.2985854324728863,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006481073,0.0003922761,0.004191629,0.0001604337,0.0001327145,0.00009567719,0.0005538067,0.0003104364,0.00004952836],"category_scores_gemma":[0.000511426,0.000260303,0.0004694821,0.0002841793,0.00003986026,0.000233176,0.0006624998,0.0002982403,0.0001220163],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002213725,"about_ca_system_score_gemma":0.001488285,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008889344,"about_ca_topic_score_gemma":0.0004940047,"domain_scores_codex":[0.9969685,0.000492982,0.001247376,0.0006516327,0.0003149302,0.0003245767],"domain_scores_gemma":[0.9975709,0.000164017,0.00072219,0.000683782,0.0005316277,0.0003275028],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.000005101059,0.000004969388,0.00001299733,0.6436969,0.00009345925,0.00002108952,0.0002461231,7.305565e-10,1.057326e-8,0.00002544203,0.001505259,0.3543886],"study_design_scores_gemma":[0.0002920406,0.00067738,0.00001831307,0.6810483,0.00567005,0.00006385435,0.0006722423,5.106237e-9,1.264748e-7,0.00000480661,0.3113622,0.0001906657],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[9.649428e-7,0.9743441,0.00003851571,0.002732237,0.0001383777,0.01988093,0.0003137023,0.00003660729,0.002514565],"genre_scores_gemma":[0.00006798156,0.9922487,0.0004136203,0.001855375,0.0001769648,0.003395968,0.0007322269,0.00005103358,0.001058133],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.3541979,"threshold_uncertainty_score":0.9999849,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4394835388","doi":"10.1016/j.esmoop.2024.102992","title":"ESMO expert consensus statements on the screening and management of financial toxicity in patients with cancer","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":54,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"Medical Research Council; EMD Serono; Ipsen; Syöpäsäätiö; European Society for Medical Oncology; Incyte; Finnish Cancer Institute; Cilag; Astellas Pharma; Associazione Italiana di Oncologia Medica; Association canadienne des infirmières en oncologie; Medtronic; Daiichi Sankyo Europe; Sanofi; Les Laboratories Pierre Fabre; AstraZeneca; Veracyte; Pfizer","keywords":"Psychosocial; Medicine; Quality of life (healthcare); Finance; Family medicine; Business; Nursing; Psychiatry","retraction":null,"screen_n_in":null,"score":{"opus":0.04935127432807665,"gpt":0.2964771593340301,"spread":0.2471258850059534,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003496216,0.0001272017,0.0002733651,0.00008951981,0.00006361431,0.0001119897,0.000244,0.00004320037,0.0002953825],"category_scores_gemma":[0.00001568998,0.0001021741,0.0000271011,0.0001419439,0.00007416336,0.0002336689,0.0001517277,0.0001082128,0.00002431784],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000922552,"about_ca_system_score_gemma":0.00002871071,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004461685,"about_ca_topic_score_gemma":0.0006886536,"domain_scores_codex":[0.9990634,0.00001020225,0.0003683774,0.0003142665,0.00003601084,0.0002077301],"domain_scores_gemma":[0.9995787,0.00004050296,0.0001357132,0.0001917362,0.00001456548,0.00003874128],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.000663668,0.0002166115,0.5191041,0.0001370621,0.0002417808,0.00002073075,0.001278144,0.0002770435,5.073981e-7,0.4152105,0.01165228,0.05119758],"study_design_scores_gemma":[0.001269755,0.000163982,0.9477761,0.0003943166,0.000005488317,1.44444e-7,0.00005861939,0.0002661399,0.00005041276,0.003832875,0.04598274,0.0001994331],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9736931,0.000675327,0.0001244009,0.00129855,0.0002493069,0.0007030483,0.0002214465,0.000008411295,0.02302637],"genre_scores_gemma":[0.9976347,0.0005276003,0.0003235688,0.000706339,0.00002729109,0.00009067591,0.000006048109,0.00001773256,0.0006660333],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.428672,"threshold_uncertainty_score":0.6744763,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2334461454","doi":"10.1136/esmoopen-2016-000040","title":"International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries","year":2016,"lang":"en","type":"article","venue":"ESMO Open","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Public Health Ontario; University of Toronto","funders":"Amgen","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Oncology; Internal medicine; Radiation therapy; Cancer; Hormone therapy; Orchiectomy; Gynecology; Breast cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.07717180705185608,"gpt":0.4148424375229098,"spread":0.3376706304710537,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005405128,0.00007276728,0.000189006,0.00008607044,0.00002554024,0.00002225761,0.0001604282,0.00001910889,0.0004137823],"category_scores_gemma":[0.0001041038,0.00004193583,0.0000223449,0.0001189538,0.00005973141,0.0001730156,0.00005323672,0.00003069666,0.000007469228],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001422522,"about_ca_system_score_gemma":0.0004538662,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006247502,"about_ca_topic_score_gemma":0.001694249,"domain_scores_codex":[0.9993037,0.00003641971,0.0001887309,0.0001595697,0.0001676327,0.0001439596],"domain_scores_gemma":[0.999369,0.0001703562,0.00007277716,0.0001228428,0.0002219286,0.0000430465],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004046548,0.000120142,0.943979,0.00003992681,0.0001670134,0.000007198194,0.0003885602,0.000002192511,0.001132007,0.00004205313,0.00210491,0.04797046],"study_design_scores_gemma":[0.01267925,0.000307895,0.9279616,0.0002291213,0.00001088235,0.000002153511,0.00003591393,0.0000693441,0.03829805,0.0002517597,0.0200736,0.00008040977],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.99143,0.0002850909,0.0001301164,0.004413772,0.000124028,0.002341063,0.000574619,0.000006168091,0.0006951283],"genre_scores_gemma":[0.9917525,0.003491826,0.0002269942,0.0001270222,0.00002309088,0.0005238684,0.0001688601,0.00001398089,0.003671858],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04789005,"threshold_uncertainty_score":0.9444396,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4381848427","doi":"10.1016/j.esmoop.2023.101587","title":"Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"William Osler Health System; Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Medicine; Reflex; Lung cancer; Intensive care medicine; Biomarker; Medical physics; Pathology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1801123491022743,"gpt":0.4606255245699017,"spread":0.2805131754676274,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002710542,0.00008606244,0.0001254972,0.00006787813,0.0002908147,0.0000647178,0.00003902056,0.00003088532,0.00006653056],"category_scores_gemma":[0.0002533295,0.00006271009,0.00002271748,0.0001586094,0.00003392538,0.00004006513,0.00002723992,0.00003570818,0.000002200874],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001031254,"about_ca_system_score_gemma":0.0003098139,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00191734,"about_ca_topic_score_gemma":0.00234305,"domain_scores_codex":[0.9993677,0.00003214496,0.0001924216,0.0002020869,0.00005589295,0.0001497953],"domain_scores_gemma":[0.9983135,0.001357379,0.00007231754,0.0001055863,0.0001171407,0.00003404111],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"observational","study_design_scores_codex":[0.001628067,0.0006716187,0.2030379,0.0005740267,0.001685067,0.0001879184,0.02710812,0.0005606865,0.03262575,0.00964771,0.6901975,0.03207562],"study_design_scores_gemma":[0.06320261,0.003315481,0.7811775,0.001120798,0.001370104,0.00007317135,0.04891092,0.03665817,0.03551597,0.01049246,0.0170511,0.001111742],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9468852,0.0001395038,0.0001476791,0.03603108,0.0001977903,0.01199449,0.000785511,0.00006076869,0.003758019],"genre_scores_gemma":[0.9806062,0.00003828937,0.008189362,0.002389546,0.00005471896,0.007627139,0.0005785552,0.00002185911,0.0004943197],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6731464,"threshold_uncertainty_score":0.2898458,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2757470630","doi":"10.1136/esmoopen-2017-000225","title":"Do patients with reduced or excellent performance status derive the same clinical benefit from novel systemic cancer therapies? A systematic review and meta-analysis","year":2017,"lang":"en","type":"review","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; Hospital for Sick Children; Public Health Ontario; University of Toronto; SickKids Foundation; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Meta-analysis; Subgroup analysis; Systemic therapy; Clinical trial; Randomized controlled trial; Clinical endpoint; Cancer; Oncology; Systematic review; MEDLINE; Breast cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.2582754661844742,"gpt":0.4876232192284989,"spread":0.2293477530440247,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006504327,0.0006051597,0.009197087,0.00008654795,0.0003280884,0.0002752534,0.0007114257,0.0001620161,0.0007606894],"category_scores_gemma":[0.0001148141,0.0002233286,0.001100455,0.0002951249,0.0001113327,0.0001704479,0.0002446732,0.0003399098,0.00002796491],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003028493,"about_ca_system_score_gemma":0.0009169775,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00366582,"about_ca_topic_score_gemma":0.0007836034,"domain_scores_codex":[0.996694,0.0002996744,0.001466659,0.0007861924,0.0004488028,0.0003047102],"domain_scores_gemma":[0.9949191,0.0004132071,0.002223575,0.001928449,0.0003110919,0.0002045774],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.00007526022,0.0002559962,0.0006141809,0.4028914,0.5708858,0.000009073033,0.0004961445,9.447759e-7,2.540372e-9,0.000007058764,0.0002300074,0.02453419],"study_design_scores_gemma":[0.001010891,0.0001859315,0.0009226559,0.1211716,0.8233215,0.00001216221,0.00005277304,0.000001897484,1.741117e-8,7.295516e-7,0.05306392,0.0002558792],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001894081,0.9830996,0.000004983541,0.000275821,0.00009854727,0.0147796,0.001343935,0.00001367072,0.0001943726],"genre_scores_gemma":[0.0006735492,0.9863908,0.0002091685,0.0005620159,0.00005023612,0.007032379,0.0006111405,0.00006614958,0.004404537],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.2817197,"threshold_uncertainty_score":0.9107075,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4288987527","doi":"10.1016/j.esmoop.2022.100530","title":"Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"EMD Serono; Genentech; Relay Therapeutics; Tessa Therapeutics; Aptose Biosciences; Banco Bilbao Vizcaya Argentaria; BeiGene; Jounce Therapeutics; Lilly Oncology; Bayer Fund; Mirati Therapeutics; Halozyme; Regeneron Pharmaceuticals; Boston Scientific Corporation; Fundación BBVA; F. Hoffmann-La Roche; AbbVie; Novartis; Celgene; Medtronic; Fundación Cellex; Les Laboratories Pierre Fabre; Meso Scale Diagnostics; Sanofi; Mersana Therapeutics; Merck; GlaxoSmithKline; Eli Lilly and Company; “la Caixa” Foundation; Bristol-Myers Squibb; AstraZeneca; Roche; Astellas Pharma US; Amgen; Boehringer Ingelheim; Pfizer; National Cancer Institute; Servier; Gilead Sciences; Taiho Pharmaceutical; Conquer Cancer Foundation","keywords":"Medicine; Pharmacodynamics; Pharmacokinetics; Adverse effect; Immunogenicity; Oncology; Internal medicine; Cancer; Antibody; Response Evaluation Criteria in Solid Tumors; Pharmacology; Monoclonal antibody; Toxicity; Phases of clinical research; Immunology","retraction":null,"screen_n_in":null,"score":{"opus":0.05214843498204853,"gpt":0.4088325772980611,"spread":0.3566841423160125,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000308485,0.0002167367,0.0007174183,0.000268473,0.0004567901,0.00003863281,0.0003936097,0.00003658789,0.001783402],"category_scores_gemma":[0.00008623273,0.000215218,0.0001560526,0.0002587423,0.00004138568,0.0002195468,0.0004160216,0.0003783001,0.000005054398],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003234085,"about_ca_system_score_gemma":0.0002664243,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001699494,"about_ca_topic_score_gemma":0.0005096142,"domain_scores_codex":[0.9981633,0.00007442494,0.0006850803,0.0004535057,0.0003228128,0.0003008057],"domain_scores_gemma":[0.9989611,0.0001100675,0.0002888673,0.0004197149,0.0001188275,0.0001014339],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.004614586,0.01930672,0.02816386,0.0002353111,0.0004220566,0.0003910822,0.01064173,0.001452356,0.9279683,0.0003068229,0.004965814,0.001531358],"study_design_scores_gemma":[0.2088132,0.05731695,0.1363311,0.001201642,0.0005940264,0.0002446232,0.02960068,0.006828301,0.4943366,0.0003467879,0.06248858,0.001897501],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9953094,0.00002683995,0.00003806256,0.0001100881,0.0003241047,0.003058037,0.0001995513,0.00003868405,0.0008952142],"genre_scores_gemma":[0.9980725,0.0000029736,0.0002221278,0.0001041931,0.0001243824,0.0004712653,0.0002627345,0.00005113359,0.0006886661],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4336317,"threshold_uncertainty_score":0.9991291,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3159801410","doi":"10.1016/j.esmoop.2021.100113","title":"Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours","year":2021,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Daiichi Sankyo Europe; Janssen Pharmaceuticals; National Cancer Institute; Bayer Yakuhin; Ignyta; Loxo Oncology; Eli Lilly Japan; Chugai Pharmaceutical; AstraZeneca; Genentech; Pfizer Japan; Bavarian Nordic; Ipsen; Exelixis; European Medicines Agency; PharmaMar; Celgene; Yakult Honsha; Bayer; Astellas Pharma; Eisai; Daiichi-Sankyo; AstraZeneca España; Ludwig Center at Harvard; Bristol-Myers Squibb; Teva Pharmaceutical Industries; Roche España; Nippon Kayaku; BeiGene; Les Laboratories Pierre Fabre; Helsinn; Boehringer Ingelheim Japan; Taiho Pharmaceutical; Lung Cancer Research Foundation; F. Hoffmann-La Roche; Amgen; Ariad Pharmaceuticals; Ono Pharmaceutical; Takeda Pharmaceutical Company; Novartis Pharma; AbbVie; G1 Therapeutics; Roche; Merck Sharp and Dohme; Novartis; Kissei; Merck; Kyowa Hakko Kirin; Sanofi; Foundation Medicine; GlaxoSmithKline; Servier; Incyte; Pfizer; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Canadian Asian Studies Association; Boehringer Ingelheim España; Eli Lilly and Company; Society for Academic Continuing Medical Education","keywords":"Medicine; Quality of life (healthcare); Clinical trial; Oncology; Internal medicine; Cancer; Lung cancer; Phases of clinical research; ROS1; Adenocarcinoma","retraction":null,"screen_n_in":null,"score":{"opus":0.01802147598297016,"gpt":0.3685137426483788,"spread":0.3504922666654087,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009848941,0.0002938656,0.0007196508,0.00005112357,0.0003664659,0.00007136085,0.0001130374,0.0000769947,0.0004646174],"category_scores_gemma":[0.00008061124,0.0002405699,0.0001197625,0.0002409154,0.00004058401,0.0001563568,0.000391216,0.0001119039,0.000001616864],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00028495,"about_ca_system_score_gemma":0.0007731366,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02037309,"about_ca_topic_score_gemma":0.005130378,"domain_scores_codex":[0.9981608,0.0000756959,0.0005284661,0.0006353991,0.0002901413,0.0003094998],"domain_scores_gemma":[0.9983426,0.0002018714,0.0003456639,0.0003632604,0.0005181068,0.0002285044],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003327249,0.01584714,0.9100898,0.00008709983,0.004514187,0.0009025818,0.04202963,0.00003700926,0.002631113,0.00002055838,0.004217078,0.01629654],"study_design_scores_gemma":[0.05775047,0.005558145,0.8770282,0.0006808668,0.005996913,0.00003128014,0.02592685,0.0004452745,0.02558393,0.00007227799,0.0004252392,0.0005005869],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9888981,0.0003414327,0.0001034992,0.0009651577,0.0004312489,0.004870715,0.002572681,0.00002242352,0.001794717],"genre_scores_gemma":[0.9957911,0.00005440933,0.001064411,0.0005280038,0.00006488819,0.0006263924,0.0008843417,0.00003197426,0.0009544213],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05442322,"threshold_uncertainty_score":0.9861503,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3041579002","doi":"10.1136/esmoopen-2020-000673","title":"Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma","year":2020,"lang":"en","type":"article","venue":"ESMO Open","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharma","keywords":"Temozolomide; Concomitant; Medicine; Glioblastoma; Radiation therapy; Oncology; Internal medicine; Open label; Clinical trial; Cancer research","retraction":null,"screen_n_in":null,"score":{"opus":0.03380584647365548,"gpt":0.3106767153573926,"spread":0.2768708688837371,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001718894,0.0002693658,0.0007113144,0.0001431126,0.00005722628,0.0001068851,0.0002419315,0.00005594214,0.00003967541],"category_scores_gemma":[0.00007409008,0.0001577876,0.000009033483,0.0006153907,0.00005853584,0.0004765757,0.0001186311,0.0001413161,0.0000025566],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001200033,"about_ca_system_score_gemma":0.0001515357,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003832642,"about_ca_topic_score_gemma":0.01006663,"domain_scores_codex":[0.9983645,0.0001557214,0.0004244303,0.0004964505,0.0003293852,0.0002295294],"domain_scores_gemma":[0.998933,0.0002024729,0.0002895666,0.0002746533,0.000130529,0.0001698219],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.04750469,0.02823987,0.9060903,0.00002559231,0.0002238335,0.0005623538,0.004461326,0.00005610602,0.00003674225,0.00001308075,0.0001113655,0.01267474],"study_design_scores_gemma":[0.3051899,0.05053639,0.6404307,0.0002360699,0.00008377797,0.000003949058,0.001810757,0.0004425285,0.001043958,0.000001538606,0.0000615856,0.0001587293],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9897578,0.00005089773,0.000002843895,0.001004838,0.00001379537,0.009050156,0.00001908977,0.00001442739,0.00008610429],"genre_scores_gemma":[0.9984086,0.00004845416,0.0005790008,0.0003957381,0.000007915025,0.0004467753,0.00006509049,0.00003844443,0.000009946051],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2656595,"threshold_uncertainty_score":0.6434392,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4310798566","doi":"10.1016/j.esmoop.2022.100634","title":"Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Hospital Foundation","funders":"Ministero della Salute; Amgen; Prostate Cancer Foundation","keywords":"Nivolumab; Medicine; Ipilimumab; Renal cell carcinoma; Internal medicine; Overall survival; Oncology; Progression-free survival; Expanded access; Response Evaluation Criteria in Solid Tumors; Urology; Cancer; Progressive disease; Disease; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.0410528661734179,"gpt":0.2901908751238391,"spread":0.2491380089504212,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005269823,0.0001638079,0.0003088483,0.0001106631,0.0001522313,0.00007793682,0.0005217305,0.0000212204,0.00007954203],"category_scores_gemma":[0.00004043072,0.00009212334,0.00004148114,0.000584678,0.0000652301,0.0002084513,0.0005007114,0.0002109362,5.719596e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001993209,"about_ca_system_score_gemma":0.0001257173,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00277136,"about_ca_topic_score_gemma":0.001873438,"domain_scores_codex":[0.998273,0.0003529724,0.0003391736,0.0003098879,0.0005148032,0.0002101893],"domain_scores_gemma":[0.999123,0.00009943495,0.0002028099,0.0004765771,0.00005465012,0.00004355771],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.000857491,0.001113453,0.9924452,0.00009769688,0.00002809276,0.00004628964,0.002620971,0.0002286315,0.00002547161,0.000007455213,0.0001289311,0.002400276],"study_design_scores_gemma":[0.007891296,0.001813322,0.9845666,0.0001159964,0.0001191398,0.0000152205,0.000666767,0.0001128181,0.004447145,0.00006145696,0.0000852159,0.0001050161],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940019,0.00005564894,0.000001241672,0.0005528655,0.00003891416,0.00399788,0.00001480989,0.000007083571,0.001329686],"genre_scores_gemma":[0.9988095,0.000002930882,0.0002092139,0.00009301448,0.000008729562,0.0006239466,0.00009491869,0.00002218213,0.0001355994],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007878634,"threshold_uncertainty_score":0.4189486,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4214857206","doi":"10.1016/j.esmoop.2022.100407","title":"Site-specific therapy in cancers of unknown primary site: a systematic review and meta-analysis","year":2022,"lang":"en","type":"review","venue":"ESMO Open","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Medicine; Meta-analysis; Internal medicine; Subgroup analysis; Cochrane Library; Hazard ratio; Confidence interval; Oncology; Combination therapy","retraction":null,"screen_n_in":null,"score":{"opus":0.2095376817135196,"gpt":0.4076122016829423,"spread":0.1980745199694227,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001004592,0.0004403611,0.01339137,0.0003279401,0.00004166263,0.00004145336,0.0003349273,0.00008574597,0.008143022],"category_scores_gemma":[0.00002861879,0.0002644139,0.00208111,0.001367933,0.00003791454,0.0000486744,0.000256957,0.0002535174,0.00001731035],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009099192,"about_ca_system_score_gemma":0.0004707958,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004272165,"about_ca_topic_score_gemma":0.001438691,"domain_scores_codex":[0.9969951,0.0005327545,0.001296679,0.0006131819,0.0003755655,0.0001867235],"domain_scores_gemma":[0.9975658,0.0003810976,0.0008499519,0.001064755,0.00004329621,0.00009506547],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001451485,0.0002386103,0.00003082519,0.8186517,0.1548679,0.00009474962,0.0001184366,8.906952e-7,8.826735e-9,0.00003288646,0.002442671,0.02350688],"study_design_scores_gemma":[0.0002738927,0.00009763006,0.00001984095,0.02689089,0.4358806,0.00001345592,0.000004492775,1.040325e-7,6.998393e-8,8.823087e-7,0.536689,0.0001291496],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000002448717,0.9877361,2.304326e-7,0.0002531134,0.0000242423,0.009842779,0.0002452317,0.000007060271,0.001888812],"genre_scores_gemma":[0.000006350681,0.9890064,0.00006164722,0.000777819,0.00001183938,0.007842938,0.0006686024,0.00004304341,0.001581342],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.7917608,"threshold_uncertainty_score":0.9999808,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3043725666","doi":"10.1136/esmoopen-2020-000672","title":"Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study","year":2020,"lang":"en","type":"article","venue":"ESMO Open","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharma; Novartis Pharmaceuticals Corporation","keywords":"Carboplatin; Medicine; Open label; Lomustine; Internal medicine; Oncology; Glioblastoma; Phases of clinical research; Randomized controlled trial; Clinical trial; Chemotherapy; Cisplatin; Vincristine","retraction":null,"screen_n_in":null,"score":{"opus":0.05163462450066753,"gpt":0.3471709034432321,"spread":0.2955362789425646,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002455646,0.0003821034,0.001026114,0.0001066387,0.0001467438,0.0001790319,0.0005460031,0.00006295917,0.0007091446],"category_scores_gemma":[0.0003522785,0.0002228158,0.0000388016,0.0006552935,0.00003610368,0.0002851037,0.0008499231,0.0002383888,0.00006420688],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002112717,"about_ca_system_score_gemma":0.0002594674,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001442496,"about_ca_topic_score_gemma":0.002548974,"domain_scores_codex":[0.9976257,0.000157398,0.0006014018,0.0007337225,0.0004689755,0.0004127941],"domain_scores_gemma":[0.9985669,0.0001422653,0.0002265244,0.0004702905,0.0001534922,0.0004405449],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5419088,0.09043612,0.319052,0.0001128727,0.001119199,0.003715967,0.01032219,0.00007778822,0.00003930077,0.000008752011,0.009696696,0.02351032],"study_design_scores_gemma":[0.855256,0.03352359,0.1050379,0.0004042494,0.0005936119,0.000006067473,0.0008652296,0.001616853,0.0004243146,0.000001100698,0.00188876,0.0003822821],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9826888,0.00005709499,0.000002449547,0.001343217,0.0001050677,0.01499649,0.00005442125,0.00003822392,0.0007142342],"genre_scores_gemma":[0.9972672,0.00001016962,0.0006449468,0.0005866447,0.00005458988,0.001077626,0.0001329024,0.00005300373,0.000172871],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3133473,"threshold_uncertainty_score":0.9086165,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3080816877","doi":"10.1136/esmoopen-2020-000842","title":"Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis","year":2020,"lang":"en","type":"review","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Centre Intégré de Santé et de Services Sociaux des Laurentides; Hôpital Charles-Le Moyne","funders":"Seagen; Servier; G1 Therapeutics; Amgen; Pfizer; Genomic Health; Genentech; AstraZeneca; Eli Lilly and Company","keywords":"Meta-analysis; Breast cancer; Hormone receptor; Oncology; Medicine; Internal medicine; Cancer; HER2 negative; Hormone therapy; Endocrine system; Hormone; Metastatic breast cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.08004028103045263,"gpt":0.3948734691561016,"spread":0.314833188125649,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.000558722,0.001280892,0.01923513,0.0002778654,0.0001200395,0.00009009587,0.0007222003,0.0001789811,0.001264788],"category_scores_gemma":[0.00008444121,0.0008268571,0.002124327,0.002859941,0.0001373431,0.0002824827,0.0002564542,0.000620795,0.00004976612],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008455492,"about_ca_system_score_gemma":0.000577889,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001508911,"about_ca_topic_score_gemma":0.0002956774,"domain_scores_codex":[0.994417,0.001345407,0.001757893,0.001364076,0.000492267,0.0006233921],"domain_scores_gemma":[0.9961557,0.0005835799,0.001575873,0.001131668,0.0002108003,0.0003423674],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.0005365387,0.0002815667,0.00002337368,0.3502613,0.3949622,0.0002152503,0.000115771,0.00003836142,2.983958e-7,0.00001960944,0.0002063575,0.2533394],"study_design_scores_gemma":[0.002899506,0.00032905,0.0001262169,0.161662,0.7089428,0.0001242699,0.00002457748,0.000006444955,0.000002401172,0.00001994151,0.1250405,0.0008222337],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[6.003087e-7,0.9798998,0.00004238119,0.002000683,0.00004563028,0.01660798,0.001142324,0.00005859643,0.0002020439],"genre_scores_gemma":[0.0000230424,0.9816136,0.002163366,0.00214371,0.00009817896,0.01232779,0.0006517644,0.0001732536,0.0008053048],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.3139807,"threshold_uncertainty_score":0.9999943,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4221092886","doi":"10.1016/j.esmoop.2022.100419","title":"Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Merck Sharp and Dohme; Genentech; Novartis Farmacéutica; Servier; Oncolytics Biotech; Else Kröner-Fresenius-Stiftung; Cancer Research UK; AstraZeneca España; Tessa Therapeutics; Eli Lilly and Company; Boehringer Ingelheim España; Novartis; Celgene; Roche España; F. Hoffmann-La Roche; Roche; NordForsk; Ernst Schering Foundation; GlaxoSmithKline España; Wilhelm Sander-Stiftung; Amgen; Pfizer; Bristol-Myers Squibb; Sanofi; MedImmune; Merck","keywords":"Medicine; Atezolizumab; Internal medicine; Clinical endpoint; Interim analysis; Hazard ratio; Lung cancer; Oncology; Surgery; Cancer; Confidence interval; Clinical trial; Gastroenterology; Pembrolizumab; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.09255978133815697,"gpt":0.4642404448781073,"spread":0.3716806635399503,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006831727,0.000160296,0.0005500162,0.0002090162,0.000224122,0.00001661394,0.0006710341,0.00003487603,0.002237116],"category_scores_gemma":[0.0001112576,0.0001596989,0.00005175953,0.0005669905,0.00006156642,0.0001201327,0.000757887,0.0004700786,0.000008962208],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001042762,"about_ca_system_score_gemma":0.0007204586,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.04076487,"about_ca_topic_score_gemma":0.00866337,"domain_scores_codex":[0.997814,0.0002044265,0.0004623233,0.0004571778,0.0006620917,0.0003999702],"domain_scores_gemma":[0.9989221,0.00008431572,0.0001109721,0.0006650889,0.00008050343,0.0001370377],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.04204327,0.04586055,0.3549044,0.0002188593,0.0008407053,0.001427363,0.06591828,0.02081599,0.02768619,0.00004117652,0.008383836,0.4318593],"study_design_scores_gemma":[0.4072911,0.09151485,0.1437735,0.0004207419,0.0001602352,0.00007509437,0.05664677,0.03533684,0.04884719,0.0001166123,0.2144314,0.001385654],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924663,0.0001289178,0.000006095487,0.0004543081,0.0001807819,0.004504402,0.00004262529,0.00002425249,0.002192283],"genre_scores_gemma":[0.9957134,0.00006977127,0.00034069,0.0002651875,0.00003678665,0.00182209,0.00002559768,0.00005245363,0.001673988],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4304737,"threshold_uncertainty_score":0.998675,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3130302511","doi":"10.1016/j.esmoop.2020.100043","title":"Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial","year":2021,"lang":"en","type":"article","venue":"ESMO Open","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre","funders":"Medical Research Council; Canadian Cancer Society Research Institute; Cancer Research UK; Cancer Australia; Canadian Cancer Society; AstraZeneca","keywords":"Medicine; Hazard ratio; Internal medicine; Clinical endpoint; Chemotherapy; Placebo; Ovarian cancer; Maintenance therapy; Progression-free survival; Oncology; Randomized controlled trial; Confidence interval; Surgery; Cancer; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.03323966290094998,"gpt":0.3371386250839932,"spread":0.3038989621830432,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005451408,0.0001900969,0.0008188608,0.00007585729,0.00004583047,0.00003939376,0.00008961296,0.0000864,0.00072783],"category_scores_gemma":[0.0001527584,0.0001529546,0.00007955563,0.0002467759,0.00002738079,0.0001052649,0.00003413338,0.0001011598,0.000002329353],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000385715,"about_ca_system_score_gemma":0.0006795952,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002563731,"about_ca_topic_score_gemma":0.002324178,"domain_scores_codex":[0.9984203,0.00009977456,0.0004986991,0.0004681341,0.0002341773,0.0002789045],"domain_scores_gemma":[0.9987777,0.000340148,0.000199668,0.0003205372,0.0002092851,0.0001526999],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9750944,0.001815677,0.00009850386,0.00003725372,0.0006987495,0.0001591009,0.004175573,0.00004271283,0.0009156217,0.0002047052,0.004621334,0.01213638],"study_design_scores_gemma":[0.9560712,0.004163835,0.006376031,0.000496418,0.0001263661,0.000005591141,0.0004558116,0.00007513902,0.02271698,0.00009352302,0.009231762,0.0001873305],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9742157,0.00002134911,0.0001947067,0.007243156,0.000361827,0.008305881,0.001118531,0.00001784013,0.008520992],"genre_scores_gemma":[0.9918178,0.00005689075,0.001436234,0.001151923,0.0003078395,0.002846313,0.0004454161,0.00003889225,0.001898668],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02180135,"threshold_uncertainty_score":0.7969228,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4405050504","doi":"10.1016/j.esmoop.2024.103972","title":"Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; Foundation Medicine; XBiotech; EMD Serono; Genentech; National Institutes of Health; HCA Healthcare; Pfizer; Incyte; Moderna; Revolution Medicines; Gilead Sciences; National Cancer Institute; Vertex Pharmaceuticals; F. Hoffmann-La Roche; Eli Lilly and Company; AstraZeneca; Jounce Therapeutics; Celgene; Array BioPharma; Astellas Pharma; TG Therapeutics; Seagen; Agios Pharmaceuticals","keywords":"Atezolizumab; Metastatic Urothelial Carcinoma; Urothelial carcinoma; Oncology; Medicine; Urothelial cancer; Internal medicine; Urology; Phase (matter); Bladder cancer; Cancer; Chemistry; Immunotherapy; Nivolumab","retraction":null,"screen_n_in":null,"score":{"opus":0.0958352596985449,"gpt":0.4042303405836028,"spread":0.3083950808850579,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002721769,0.0002422753,0.0005815718,0.0001028843,0.0002640481,0.0002308193,0.0003835799,0.00005709979,0.00229382],"category_scores_gemma":[0.0000349171,0.0001458846,0.000483405,0.0004699389,0.00005916221,0.0001504156,0.00009200665,0.0001570172,0.00006660426],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001043991,"about_ca_system_score_gemma":0.0004876858,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01006331,"about_ca_topic_score_gemma":0.0006587002,"domain_scores_codex":[0.9985353,0.00008751323,0.0003434516,0.0004942166,0.0002565069,0.0002830182],"domain_scores_gemma":[0.9990082,0.0002537075,0.00005875839,0.0005140607,0.00005153182,0.0001137527],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4856434,0.006405748,0.003031535,0.000154796,0.04887893,0.0008303361,0.01384655,0.00005554042,0.001162546,0.003319768,0.106512,0.3301588],"study_design_scores_gemma":[0.4822514,0.01509852,0.005552967,0.0001334939,0.02875086,0.00003299289,0.0004591062,0.007427298,0.006565718,0.005602032,0.4474281,0.0006974765],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9701455,0.002431052,0.004754378,0.008820093,0.001221055,0.007027092,0.002310345,0.0001146011,0.003175836],"genre_scores_gemma":[0.9887794,0.00005943868,0.001264061,0.001260504,0.0009768591,0.001041495,0.0004918468,0.00005495344,0.006071493],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3409161,"threshold_uncertainty_score":0.9986182,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4407227498","doi":"10.1016/j.esmoop.2024.104121","title":"Sinonasal malignancy: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Head and Neck Surgical Oncology","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Surgical Specialties (Canada)","funders":"Swedish Orphan Biovitrum; European Society for Medical Oncology; Eisai; Seagen; Incyte; Multinational Association of Supportive Care in Cancer; American Society of Clinical Oncology; AstraZeneca; European SocieTy for Radiotherapy and Oncology; Regeneron Pharmaceuticals; Medpace; Associazione Italiana di Oncologia Medica; Gilead Sciences; Sanofi; Celgene; Adenoid Cystic Carcinoma Research Foundation; Pfizer","keywords":"Guideline; Medicine; Malignancy; Clinical Practice; Intensive care medicine; Internal medicine; Physical therapy; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.08541978819751062,"gpt":0.4921159938210979,"spread":0.4066962056235873,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001184433,0.0001866531,0.0007530096,0.00005471378,0.0001279677,0.00004861967,0.0001672297,0.0002213613,0.0002747266],"category_scores_gemma":[0.00270338,0.0001368299,0.0001563002,0.0001408994,0.0000917251,0.0001527732,0.0001938828,0.0001571282,0.00003668613],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001035442,"about_ca_system_score_gemma":0.0005781516,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001042326,"about_ca_topic_score_gemma":0.0003947078,"domain_scores_codex":[0.9981223,0.0001863851,0.0007896614,0.0004891262,0.0001045065,0.0003080259],"domain_scores_gemma":[0.9964892,0.00260447,0.0001330855,0.0003387891,0.0001951189,0.0002393159],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.004726104,0.002339227,0.1604459,0.0000619857,0.0005339635,0.0003933783,0.0001312083,5.823053e-7,0.0000189628,0.008980646,0.4468065,0.3755615],"study_design_scores_gemma":[0.01126931,0.002557141,0.0388769,0.000121891,0.0004703467,0.00004432441,0.00007520045,0.00006237441,0.0002966395,0.0003482615,0.9457526,0.0001249781],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.4039891,0.002492191,0.0006190023,0.4326828,0.003159052,0.007864365,0.0001112824,0.000148998,0.1489332],"genre_scores_gemma":[0.7060028,0.007664926,0.07483233,0.1259225,0.001789899,0.002941127,0.0005312586,0.0001109187,0.0802043],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.4989461,"threshold_uncertainty_score":0.5579761,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4401354990","doi":"10.1016/j.esmoop.2024.103647","title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"Eli Lilly Japan; Sirtex Medical; Ipsen; Kaohsiung Medical University Chung-Ho Memorial Hospital; Teijin Pharma; Japanese Society of Medical Oncology; European Society for Medical Oncology; Health Promotion Administration, Ministry of Health and Welfare; Kaohsiung Medical University; Chunghwa Telecom Laboratories; ReShape Lifesciences; Genentech; Veracyte; Astellas Pharma; Eisai; Fondazione Beretta; BeiGene; Handok; Les Laboratories Pierre Fabre; Pfizer; Incyte; Boehringer Ingelheim Japan; Taiho Pharmaceutical; Chugai Pharmaceutical; Abbott Japan; AstraZeneca; Invitae; Yuhan; Daiichi Sankyo Europe; Servier; Gilead Sciences; Halozyme; Exelixis; Sanofi; Relay Therapeutics; Amgen; Rakuten Medical; Celgene; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Biliary tract cancer; Cancer; Medicine; Biliary tract; Clinical Practice; General surgery; Internal medicine; Family medicine; Gemcitabine","retraction":null,"screen_n_in":null,"score":{"opus":0.1414069728864935,"gpt":0.4450970365877709,"spread":0.3036900637012774,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003500948,0.0001747391,0.000420507,0.00003354393,0.0001032575,0.00005744736,0.0001293182,0.0000580893,0.00005643575],"category_scores_gemma":[0.000624511,0.00008710121,0.0001208229,0.0001319933,0.00009461061,0.0001869524,0.00008833929,0.0001045207,0.000002347974],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006050808,"about_ca_system_score_gemma":0.0002749466,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004825951,"about_ca_topic_score_gemma":0.002650353,"domain_scores_codex":[0.9988515,0.00004328138,0.0004140189,0.0003503583,0.0001754903,0.0001652861],"domain_scores_gemma":[0.9981272,0.0009517304,0.0001057003,0.0002876239,0.0004550132,0.00007278923],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001680336,0.0004370262,0.6230867,0.00008306716,0.001540878,0.00002154721,0.00112083,7.673165e-7,6.036833e-7,0.00004477679,0.08004056,0.2919429],"study_design_scores_gemma":[0.003682803,0.001306047,0.6258607,0.00023729,0.001360041,0.000005202255,0.0006725125,0.00004005865,0.0000399755,0.00001129745,0.3666967,0.00008730283],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7849927,0.04913872,0.00009220452,0.1512204,0.002159335,0.00819217,0.0006139996,0.00008731822,0.003503127],"genre_scores_gemma":[0.9861943,0.007469326,0.001540898,0.002036148,0.0003621386,0.00120785,0.0000566146,0.00003625376,0.00109648],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2918556,"threshold_uncertainty_score":0.7295426,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4292411599","doi":"10.1016/j.esmoop.2022.100562","title":"Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; PharmaMar; Servier; Astellas Pharma; Eisai; Incyte; Seagen; Gilead Sciences; Ipsen; BeiGene; Sanofi; Daiichi-Sankyo; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Atezolizumab; Internal medicine; Oncology; Adverse effect; Tolerability; Cancer; Immunotherapy; Pembrolizumab","retraction":null,"screen_n_in":null,"score":{"opus":0.0494886679412191,"gpt":0.3824033392055332,"spread":0.3329146712643141,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003825031,0.0003092305,0.0007382605,0.0001711625,0.0004579587,0.0001596943,0.00106901,0.00003390767,0.0009553253],"category_scores_gemma":[0.0002179458,0.0002425758,0.00002931245,0.0004252139,0.00005048436,0.0005273239,0.003257085,0.0004790561,0.00007372],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007139581,"about_ca_system_score_gemma":0.000394824,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01771855,"about_ca_topic_score_gemma":0.002371268,"domain_scores_codex":[0.9967564,0.000306983,0.0005674392,0.0008980584,0.0008562973,0.0006148246],"domain_scores_gemma":[0.9983233,0.0001058384,0.0001960355,0.0009360426,0.000124347,0.0003144237],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4293551,0.1491953,0.3347297,0.00002704464,0.001202169,0.005460724,0.01286879,0.0001213231,0.00008097537,0.000006200405,0.003895324,0.06305736],"study_design_scores_gemma":[0.574192,0.02830125,0.3898916,0.0001777178,0.00008293458,0.000003788053,0.002162465,0.001129794,0.0001980728,0.00001250345,0.003517066,0.0003308601],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9858233,0.000024782,0.000001643855,0.0004158494,0.00008967653,0.009768686,0.001094603,0.00003215649,0.002749339],"genre_scores_gemma":[0.9928691,0.000003895088,0.001199512,0.000301548,0.00002578166,0.001466357,0.00226761,0.00005945077,0.001806793],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1448369,"threshold_uncertainty_score":0.9999579,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3106792472","doi":"10.1136/esmoopen-2020-000948","title":"Prevention of venous thromboembolism in ambulatory patients with cancer","year":2020,"lang":"en","type":"review","venue":"ESMO Open","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Jewish General Hospital; McGill University; Ottawa Hospital; University of Ottawa","funders":"Bayer","keywords":"Medicine; Apixaban; Ambulatory; Rivaroxaban; Cancer; Low molecular weight heparin; Warfarin; Anticoagulant; Regimen; Intensive care medicine; Thrombosis; Complication; Venous thromboembolism; Clinical trial; Venous thrombosis; Internal medicine; Atrial fibrillation","retraction":null,"screen_n_in":null,"score":{"opus":0.05210794562375279,"gpt":0.3764223271871719,"spread":0.3243143815634191,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001764427,0.000353897,0.003592385,0.0001447948,0.00003344081,0.00003050048,0.0004428737,0.0001759379,0.0004922552],"category_scores_gemma":[0.00001706806,0.0002623323,0.0002697054,0.0004199224,0.00005031885,0.0001234322,0.0004049799,0.0003121855,0.00004381089],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002350479,"about_ca_system_score_gemma":0.0006288836,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002048036,"about_ca_topic_score_gemma":0.0004392405,"domain_scores_codex":[0.998158,0.00009001463,0.0006444317,0.0004990013,0.0003495464,0.0002589574],"domain_scores_gemma":[0.9988104,0.00002718453,0.0005044825,0.0004715041,0.00007386069,0.0001125592],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00003131916,0.002008525,0.0006810758,0.01675816,0.001004623,0.00003159768,0.0002762672,0.00000204875,2.084808e-8,0.0002256621,0.004325667,0.974655],"study_design_scores_gemma":[0.00129772,0.0006800129,0.04029324,0.03309024,0.002387421,0.000001563545,0.00001775431,0.00000104741,7.966487e-7,0.00002456888,0.9219476,0.0002580228],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0006899328,0.9865455,0.000003916233,0.00007485452,0.0002440116,0.006684614,0.00005713991,0.00002300929,0.005676989],"genre_scores_gemma":[0.0005721469,0.9975598,0.0002413016,0.0001777643,0.00009850213,0.0006958838,0.0002970333,0.00008749774,0.0002700333],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.974397,"threshold_uncertainty_score":0.9999829,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4214935792","doi":"10.1016/j.esmoop.2022.100410","title":"Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Janssen Pharmaceuticals; Chugai Pharmaceutical; Merck Sharp and Dohme; Bristol-Myers Squibb Canada; Janssen Research and Development; EMD Serono; Genentech; Ipsen; PharmaMar; Astellas Pharma; National Institute for Health and Care Research; Seagen; G1 Therapeutics; AstraZeneca España; Daiichi-Sankyo; ViewRay; BeiGene; Meso Scale Diagnostics; Les Laboratories Pierre Fabre; TG Therapeutics; Amgen; Boehringer Ingelheim; Elekta; Taiho Pharmaceutical; Mirati Therapeutics; Varian Medical Systems; Takeda Pharmaceutical Company; AbbVie; Sanofi; Celgene; Novartis; Manchester Biomedical Research Centre; Merck; GlaxoSmithKline; Daiichi Sankyo Europe; Servier; Bayer; Bristol-Myers Squibb; Ono Pharmaceutical; Eli Lilly and Company; AstraZeneca; Incyte; Pfizer; Roche; Astellas Pharma US","keywords":"Durvalumab; Medicine; Chemoradiotherapy; Hazard ratio; Clinical endpoint; Internal medicine; Post-hoc analysis; Stage (stratigraphy); Oncology; Lung cancer; Cancer; Clinical trial; Confidence interval; Pembrolizumab; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.02197590166635086,"gpt":0.3131541527190675,"spread":0.2911782510527167,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004087114,0.0002385683,0.0007254583,0.0001087119,0.0001724253,0.0001131102,0.000414319,0.00004045161,0.004540338],"category_scores_gemma":[0.000003624153,0.0001459799,0.000156212,0.0006165003,0.00003862772,0.0001588867,0.000162644,0.000247456,0.000004361324],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007786185,"about_ca_system_score_gemma":0.0004261191,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.02493383,"about_ca_topic_score_gemma":0.02718504,"domain_scores_codex":[0.9983032,0.0002149896,0.0002917146,0.000540054,0.0003824026,0.0002676682],"domain_scores_gemma":[0.9987448,0.0001043185,0.000139178,0.0008645331,0.00003197382,0.000115165],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01308788,0.001019261,0.9756967,0.00001296683,0.00168134,0.0002030089,0.006278154,0.0003271979,0.000005891403,0.000003389998,0.00110028,0.0005838933],"study_design_scores_gemma":[0.0860191,0.001099668,0.8970167,0.00004846389,0.002009117,9.227807e-7,0.004879962,0.0005408014,0.000317537,0.000005441006,0.007741102,0.0003211669],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9928555,0.0008454067,0.00001184938,0.00271837,0.0002037538,0.002465911,0.0002311701,0.00002099667,0.0006469862],"genre_scores_gemma":[0.9901112,0.0002864505,0.0001803201,0.001566453,0.000138421,0.005881331,0.0001788409,0.00004570598,0.00161127],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07868002,"threshold_uncertainty_score":0.9963697,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4389067002","doi":"10.1016/j.esmoop.2023.102045","title":"Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Instituto de Salud Carlos III; Horizon 2020 Framework Programme; European Commission","keywords":"Alveolar soft part sarcoma; Medicine; Internal medicine; Soft tissue sarcoma; Immunotherapy; Retrospective cohort study; Sarcoma; Progressive disease; Oncology; Confidence interval; Surgery; Disease; Cancer; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.02896856907271544,"gpt":0.3037014069650634,"spread":0.274732837892348,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006600916,0.0002168946,0.0006888644,0.0001856732,0.00005820145,0.00003918534,0.0003220949,0.0001135501,0.0001738909],"category_scores_gemma":[0.001029656,0.0001864721,0.0002096504,0.0008115547,0.00009051517,0.0001153519,0.0004245353,0.0002807396,0.000247674],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002560692,"about_ca_system_score_gemma":0.0001351612,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01798567,"about_ca_topic_score_gemma":0.001100096,"domain_scores_codex":[0.9978657,0.00008096194,0.0008366032,0.0005527303,0.0003373623,0.000326601],"domain_scores_gemma":[0.998265,0.0003874889,0.0002830169,0.0008754105,0.00007045556,0.0001186029],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003730257,0.002800207,0.9498138,0.00003753383,0.0005565427,0.001785859,0.002511463,0.00002255312,0.001746488,0.0002116332,0.02616293,0.01062068],"study_design_scores_gemma":[0.012148,0.0001859685,0.9490584,0.0008376665,0.0000849343,0.000007631244,0.0003114857,0.00003111446,0.03015207,0.0004107667,0.00661394,0.0001580635],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9853604,0.0004823621,6.358622e-7,0.004422159,0.0002374722,0.001149114,0.0001367066,0.00007025292,0.008140889],"genre_scores_gemma":[0.9972231,0.0001435607,0.000344814,0.0001043861,0.0001498963,0.0001273946,0.0004934928,0.00003742603,0.001375979],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02840558,"threshold_uncertainty_score":0.9885536,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4376613834","doi":"10.1016/j.esmoop.2023.101571","title":"LBA1 Final analysis of the placebo-controlled randomised phase III IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) followed by open-label adjuvant atezo in patients (pts) with early-stage triple-negative breast cancer (eTNBC)","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Roche (Canada); McGill University; Jewish General Hospital","funders":"F. Hoffmann-La Roche; Eisai; Sanofi; Daiichi-Sankyo; Pfizer; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company","keywords":"Medicine; Atezolizumab; Internal medicine; Cyclophosphamide; Oncology; Adjuvant; Neoadjuvant therapy; Capecitabine; Placebo; Population; Breast cancer; Gastroenterology; Surgery; Chemotherapy; Cancer; Immunotherapy; Pathology; Pembrolizumab","retraction":null,"screen_n_in":null,"score":{"opus":0.03329605026677972,"gpt":0.359875093027282,"spread":0.3265790427605023,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009678893,0.0005311138,0.001703881,0.0001718755,0.0003443942,0.0001346778,0.001199267,0.0001230069,0.0002767514],"category_scores_gemma":[0.0001714457,0.0003338701,0.0003159815,0.001259573,0.0001690604,0.00004729377,0.0008175197,0.0001908816,0.000003934812],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002628753,"about_ca_system_score_gemma":0.0006015568,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01828023,"about_ca_topic_score_gemma":0.004822812,"domain_scores_codex":[0.9964333,0.0006036661,0.0009043538,0.0009038872,0.0005681662,0.0005866917],"domain_scores_gemma":[0.9978528,0.0001639079,0.0008748649,0.0007296926,0.0002564432,0.0001223178],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9629312,0.00147342,0.01325365,0.00001193579,0.006728318,0.00001122265,0.0008458624,0.001083507,0.001769396,0.000002237428,0.002598594,0.009290655],"study_design_scores_gemma":[0.939201,0.001650147,0.04827001,0.000122483,0.001396441,0.000001245947,0.0002662044,0.003059551,0.005427382,0.000005958643,0.0001570655,0.0004424881],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.988985,0.0001125191,0.0000351778,0.0005780088,0.0002184156,0.008587884,0.001208023,0.00001625451,0.000258727],"genre_scores_gemma":[0.9929057,0.0001414424,0.0001157712,0.0001612265,0.00005716,0.003543806,0.0005601101,0.00006283412,0.002451942],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03501636,"threshold_uncertainty_score":0.9999113,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3120723698","doi":"10.1016/j.esmoop.2020.100019","title":"Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)","year":2021,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Eisai Canada; European Society for Medical Oncology; Eisai; Eli Lilly and Company; Takeda Pharmaceutical Company; Roche; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; AstraZeneca","keywords":"Eribulin; Gemcitabine; Medicine; Internal medicine; Metastatic breast cancer; Triple-negative breast cancer; Oncology; Neutropenia; Regimen; Clinical endpoint; Phases of clinical research; Febrile neutropenia; Breast cancer; Adverse effect; Clinical trial; Cancer; Toxicity","retraction":null,"screen_n_in":null,"score":{"opus":0.08808522107393496,"gpt":0.4514207987133853,"spread":0.3633355776394503,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003993402,0.0002029101,0.0008976417,0.00004511128,0.00008999659,0.00000742168,0.0001705376,0.00004379705,0.0001364663],"category_scores_gemma":[0.0001200693,0.00009120864,0.00008351333,0.0003786728,0.000240309,0.00006455778,0.00007576434,0.0001022274,1.516317e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001154402,"about_ca_system_score_gemma":0.0006000674,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008366315,"about_ca_topic_score_gemma":0.005685905,"domain_scores_codex":[0.99792,0.0004159339,0.0008749276,0.0003772757,0.0002504284,0.0001614075],"domain_scores_gemma":[0.9973403,0.001235862,0.0006856517,0.0003116292,0.0003616833,0.00006483535],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7705467,0.09939826,0.05958069,0.00005902686,0.001776088,0.00002601462,0.002652188,0.0001542458,0.00006676431,0.000006180212,0.0001606992,0.06557314],"study_design_scores_gemma":[0.5228265,0.1742672,0.2968521,0.0001271324,0.001977581,0.000002118247,0.0007624151,0.0001038334,0.002530336,0.000008571688,0.0004527602,0.0000893941],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9863081,0.0001067699,0.000004918503,0.001321652,0.0002026817,0.01116791,0.0008158285,0.000003573507,0.00006855666],"genre_scores_gemma":[0.9972127,0.0004537283,0.000212451,0.0001386519,0.00002783886,0.001380598,0.00008318239,0.00001815967,0.000472653],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2477202,"threshold_uncertainty_score":0.371938,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}